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Qin, Liang. Ph.D., Purdue University, August 2016. Insights into Substrate Recognition by 
the Anaphase Promoting Complex (APC). Major Professor: Mark Hall. 
 
 
        Mitotic exit depends on the proper degradation of numerous cell cycle-regulated 
proteins, which is executed by an E3 ubiquitin ligase called the anaphase promoting 
complex (APC). APC adds polyubiquitin chains to numerous substrates, which leads to 
their subsequent degradation in late mitosis and G1 phase. The selective and timely 
recognition and degradation of APC substrates is essential for proper cell cycle 
progression and maintenance of genome stability. However, a key question is how APC 
specifically recognizes such a diversity of substrates. The activation of APC requires 
binding to one of its co-activators, Cdh1 or Cdc20. The co-activators directly facilitate 
APC enzymatic activity, but also contribute to the highly selective recognition of 
substrates via binding to degrons, such as the destruction box (D-box), KEN-box, and 
ABBA motif. However, not all substrates contain these degrons. Moreover, D- and KEN-
box sequences are found in many proteins that are clearly not APC substrates, indicating 
that additional factors must contribute to recognition of these degrons. 
        APC activity is tightly regulated by pseudosubstrate inhibitors, which bind tightly to 
the degron receptor sites on the APC co-activators to competitively block substrate 
binding. Pseudosubstrate inhibitors have been identified throughout the eukaryotes, 
including in yeast, plant, and metazoan species. In budding yeast, Cdh1 is regulated by a 
pseudosubstrate inhibitor called Acm1, which uses both D-box and KEN-box motifs and 




resolution structure of the Cdh1-Acm1 complex has been solved, an important question 
still remains unanswered: what distinguishes Acm1 from true substrates to allow it to 
evade ubiquitination and degradation? The answer will help us better understand the 
requirements for APC substrate recognition and specificity.  Moreover, since APC is 
considered an attractive cancer chemotherapeutic target, knowledge of the inhibitory 
mechanism of Acm1, a natural APC inhibitor, can guide development of selective APC 
inhibitors in the future.  
        Here I found that the D-box receptor on Cdh1 is required for normal proteolysis of 
most, possibly all, APCCdh1 substrates, including many lacking consensus D-box 
sequences. In contrast, the KEN-box and ABBA motif receptors are only required for 
proteolysis of a subset of Cdh1 substrates. Moreover, Acm1 was shown to inhibit the in 
vivo proteolysis of diverse APCCdh1 substrates in budding yeast, including those without 
canonical D- and/or KEN boxes. Therefore, at least part of the substrate recognition 
mechanisms appears to be shared by all APCCdh1 substrates. 
        Moreover, I found that Acm1 can be converted into an APC substrate in vivo solely 
by mutation of its D-box degron. I identified a new component of the D-box that is 
responsible for Acm1 acting as an inhibitor. Replacing this sequence just C-terminal to 
the D-box core consensus in Acm1 with the corresponding sequence from Hsl1, a true 
substrate, is sufficient to convert Acm1 into an APCCdh1 substrate. Conversely, several 
APCCdh1 substrates can be stabilized by replacing this D-box extension (DBE) with the 
corresponding one from Acm1, and these mutant APCCdh1 substrates also acquire weak 
inhibitory function. These results together suggest that the DBE in Acm1 has unique 
properties that lead to potent APC inhibition, likely through high affinity binding coupled 
with perturbation of APC’s enzymatic activity. APCCdh1 substrates can also be stabilized 
by mutating the residues of their DBEs to just alanine. This indicates that the DBE is   
generally important for substrate processing by APCCdh1.  In summary, my study reveal 
the critical role of D-box, which includes both RxxL core sequence and the extension, in 






CHAPTER 1. INTRODUCTION 
 
1.1 Cell cycle regulation 
 
        The cell cycle is a series of events which is highly regulated by various mechanisms 
[1]. Cell cycle can be divided into four phases, G1, S, G2, and M that leads to the mother 
cell dividing into two daughter cells in a unidirectional and irreversible manner (Figure 
1.1). The completion of a whole cell cycle requires the duplication of both chromosomes 
and other cellular components. As a highly-regulated process, cell cycle progression is 
mainly controlled by a family of serine/threonine protein kinases known as cyclin-
dependent kinases (Cdks) which target numerous cell cycle regulators for 
phosphorylation [2, 3]. Cdk recognizes consensus sequence (S/T)P (additional +3 K/R is 
preferred) [4], and its activity is modulated by association with its activating regulatory 
subunits, cyclins, whose levels are periodic during the cell cycle [2]. The regulated cell 
cycle progression is critical for disease avoidance, as the dysregulation in cell division 
can result in genome instability and unrestrained cell proliferation, which are hallmarks 
of many human diseases such as cancer [1]. While higher eukaryotes have multiple Cdks, 
budding yeast Saccharomyces cerevisiae utilizes only one essential Cdk for controlling 
cell cycle, Cdk1 (Cdc28), making yeast an attractive and simple model for studying cell 
cycle control [3]. Besides Cdk1, several other Cdks exist in budding yeast: Pho85 (similar 
to mammalian Cdk5) [5, 6], Kin28 (similar to mammalian Cdk7) [7], Ssn3 (similar to 
mammalian Cdk8) [8], Ctk1 and Bur1 (both corresponding to mammalian Cdk9) [9, 10]. 
They mainly function in transcription regulation [11]. Although Cdk1 is sufficient to drive 
cell cycle progression, some of its functions are supported by other Cdks [6]. As the only 






with different cyclin subunits in different cell cycle phases. Mitotic onset requires an 
increase in Cdk1 activity caused by the dephosphorylation on a conserved inhibitory 
tyrosine (tyrosine 19 which is phosphorylated by Swe1 in budding yeast) [12]. 
Association with different types of cyclins allows it to drive many different cell division 
events, such as DNA replication, cell cycle entry, chromosome condensation, spindle 
assembly, chromosome segregation, and spindle pole body duplication [13]. For 
example, at least one of the G1 cyclins, Cln1, Cln2 or Cln3 is required for critical G1 
events such as bud emergence, spindle pole body (SPB) duplication, and expression of S 
phase-promoting cyclins [14]. Then, Cdk1 binds to the early-expressed B-type cyclins 
Clb5 and Clb6 to initiate DNA replication and drive cell cycle progression through S 
phase [14]. Mitotic events such as spindle assembly requires Cdk1 association with B-
type cyclins Clb1-4 which also prevent mitotic exit and cytokinesis [14]. To exit from 
mitosis and re-enter G1 (start another round of cell cycle), Cdk1 must be inactivated, 
which is largely achieved by the degradation of its regulatory cyclin subunits. Cyclins are 












Figure 1.1 Cell cycle 
The cell cycle has two major phases: interphase (including G1, S, and G2 phases) which 
is between mitotic events, and mitotic phase where the division of the nucleus and 
segregation of the copied genome occur. After mitosis, cytokinesis occurs which leads to 
one mother cell dividing into two daughter cells. In G1 phase, the mother cell can sense 
and integrate external signals from environment to induce cell growth by promoting 
RNA and proteins synthesis. If the environment is not suitable for cell division, the cell 
will enter G0 phase instead of growing. When the mother cell enters S phase, DNA is 
synthesized to replicate the chromosomal DNA. After entering G2 phase, the mother 
cell continues to grow and prepare for mitosis. The significance of G2 checkpoints is to 






1.2 Ubiquitin proteolysis system 
 
        Besides Cdk-mediated phosphorylation and oscillations in Cdk activity, cell cycle 
progression also requires the periodic rise and fall of numerous other regulators, which 
is tightly controlled by the interplay between protein synthesis and degradation [15, 16]. 
Regulated protein degradation depends primarily on the ubiquitin proteasome system. 
Ubiquitin is a 76-amino-acid protein [17, 18]. Three distinct enzymatic steps are involved 
in targeting proteins for degradation by the ubiquitin proteasome system: ubiquitin 
activating enzyme (E1), ubiquitin conjugating enzyme (E2), and ubiquitin ligase (E3) 
(Figure 1.2) [17, 18]. E1 activates ubiquitin by ATP-dependent formation of a covalent 
thioester bond between the E1 active site cysteine and the C-terminus of ubiquitin [17, 
18]. Then the activated ubiquitin is transferred from E1 to a cysteine SH group on E2 
which then transfers the ubiquitin to the ε-amino group of Lys residue (or rarely α-
amino group of the N-terminal amino acid) of the protein targeted by E3 for degradation 
(Figure 1.2) [17, 18]. E3 can be classified into three families based on their catalytic 
domains: the HECT domain (homologous to E6-associated protein C terminus) E3, the 
RING finger E3, and the U box E3 [17]. While HECT domain E3s  utilize a catalytic 
cysteine residue in the HECT domain to accept ubiquitin molecules from E2 before 
transferring them to substrates, the RING and U box E3 do not directly form covalent 
intermediates with ubiquitin, but bring substrate and E2 into proximity and correct 
orientation for the ubiquitin transfer to happen [17]. Therefore, RING and U box E3s 
mainly provide the specificity for the ubiquitination reaction by coordinating the 
association of distinct E2s and substrates. Ubiquitin chains are then assembled via 
ubiquitin lysine side chains by the E3/E2 pairs and finally, the polyubiquitinated proteins 
are recognized and degraded by the 26S proteasome in an ATP-dependent manner 
(Figure 1.2) [17, 18]. The 26S proteasome consists of a 20S core particle which contains 
the protease catalytic sites, and two 19S regulatory complexes which contain several 
ATPase subunits [17, 18]. Proteolysis plays a critical role in controlling cell cycle 






cycle entry. Mis-expressed cell cycle regulators are frequently observed in many types of 
human tumors [19, 20], implicating deregulated proteolysis as a contributor to cancer. 
Two related E3 ubiquitin ligases are primarily responsible for degrading cell cycle 
regulators during the cell cycle: the Skp1-cullin-F-box (SCF), and the anaphase 






















Figure 1.2 Ubiquitination system 
Coupled with the hydrolysis of ATP, the ubiquitin-activating enzyme (E1) binds to the C-
terminus of ubiquitin which leads to its activation. The activated ubiquitin then is 
transferred to the ubiquitin-conjugating enzyme (E2) which binds to the ubiquitin ligase 
(E3). Finally, the ubiquitin thioester link is attacked by a substrate lysine side chain 
leading to formation of a covalent isopeptide bond between the ubiquitin C-terminus 
and the substrates. Further rounds of catalysis involve ubiquitination of ubiquitin lysines, 












1.3 The anaphase promoting complex (APC) 
 
1.3.1 The structure and function of APC 
 
        SCF and APC control protein degradation in different cell cycle phases [15, 16, 19]. 
While SCF plays several central roles in controlling S-phase entry and mitotic entry (also 
with some functions at mitotic exit and in G1), APC mainly functions during late mitosis 
and G1 phase [15, 16, 19]. In eukaryotic cells, the final stage of mitosis, called mitotic 
exit, is tightly controlled by APC [16, 21-23]. APC is a large cullin-RING E3 ubiquitin ligase 
that consists of 15 subunits (Figure 1.3) [24-26]. The atomic structures of APC bound to 
either the pseudosubstrate inhibitor early mitotic inhibitor 1 (Emi1), or E2 ubiquitin-
conjugating enzyme UbcH10 have been determined by cryo-electron microscopy [24-26]. 
A triangular shape is adopted by APC with an inner cavity [24-26]. Four canonical 
tetratricopeptide repeat (TPR) proteins (Apc3, Apc6, Apc7, and Apc8) and their three 
accessory subunits (Apc12, Apc13, and Apc16) assemble to form the back and top of the 
complex, and Apc4, Apc5, Apc15, as well as two domains of Apc1 form the base or 
platform region [24-26]. Apc10 and Cdh1 form the substrate binding module which is 
located within the inner cavity adjacent to the Apc3 homo-dimer, and Apc2 and Apc11 
form the catalytic module which is positioned at the periphery of the platform [24-26]. 
The C-terminal domain of Apc2 associates with Apc11 and together they are located at 
the front of the cavity below Apc10 and Cdh1 [24-26]. The four TPR proteins assemble 
themselves to form V-shaped homo-dimers in a parallel hierarchical array which finally 
generate a left-handed supra-helix [24-26]. Such assembly is determined by Apc13 and 
Apc16 which span multiple TPR subunits [24-26]. 
        Two essential APC substrates are securin and the B type cyclins, whose degradation 
plays key roles in two crucial mitotic exit events: chromosome segregation and Cdk 
inactivation (Figure 1.4) [27-31]. Securin inhibits chromosome segregation by 
sequestering separase, a cysteine protease that hydrolyzes cohesin in anaphase to allow 






mitotic exit and cytokinesis in most eukaryotes. The APC targets many other proteins for 
degradation as well. They play diverse roles in cell cycle regulation and even in events 
outside the cell cycle, which indicates that APC is also involved in many other processes 
besides mitotic exit. For example, APC has functions in differentiation and metabolism 
[32], and it also plays important roles in post-mitotic cells such as neurons [33]. Recently 
identified APC targets in plants also indicate the essential role APC plays in many 
different developmental processes of plants [34]. 
        The proper activation of APC requires its binding to the co-activators, Cdc20 or 
Cdh1 [35]. Cdc20 and Cdh1 are closely related paralogs that consist of largely 
unstructured regulatory N-terminal domains and a highly conserved seven-bladed β 
propeller WD40 repeat domain. APC associates with Cdc20 first to start anaphase by 
promoting sister chromatid segregation via securin degradation, then with Cdh1 during 
late anaphase to promote mitotic exit. APC association with Cdh1 is maintained in G1 
phase until the start of S phase. Interestingly, APCCdc20 and APCCdh1 have different, but 
partly overlapping, sets of substrates, although both of them appear to recognize similar 
short motifs on the substrates [35]. APCCdc20 recognizes a limited number of substrates, 
while APCCdh1 targets a much broader set of substrates for degradation. Although the 
substrate binding sites on both Cdc20 and Cdh1 have been identified, little is known 
about the mechanism by which they recognize different substrates. APC co-activators 
perform two independent, but important tasks. First, they help recruit substrates by 
direct binding via their conserved WD40 domain. Second, their binding to APC core 
subunits through the N-terminal C-box and C-terminal IR motifs induces a 
conformational change in APC that makes APC catalytically competent [24-26, 36]. The 
N-terminal domain of Cdh1 (Cdh1NTD) is organized into two mini-domains: one interacts 
with Apc8B, and the other interacts with Apc1 [24-26]. The seven-residue C-box 
(residues 46-52) plays a critical role in directing the interaction between Cdh1NTD and 
APC via extensive contacts with Apc8 [24-26]. While Asp46, Arg47 and Arg52 in the C-
box form a network of electrostatic interactions, Phe48 and Ile49 direct non-polar 






conformation which inserts into the TPR super-helix of Apc3A [24-26]. On the IR tail of 

























Figure 1.3 APC structure 
Schematic of APC subunit topology based on biochemical and genetic data [25, 35, 37]. 
Apc2 and Apc11 engage E2-activated ubiquitin to form the catalytic center. Apc10 and 











Figure 1.4 APC and its substrates 
APC degrades numerous substrates which play diverse roles in cell cycle regulation. The 
proper activation of APC requires binding to the co-activators: Cdc20 or Cdh1. APC binds 
to Cdc20 to start anaphase, then to Cdh1 during late anaphase and G1 phase to 















1.3.2 Regulation of APC 
 
        As a major regulator of the cell cycle during late mitosis and G1 phase, APC itself is 
under intense regulation by various mechanisms. Both APC core subunits and its co-
activators can be reversibly phosphorylated, which greatly controls the selective binding 
of the co-activators to core APC. Phosphorylated APC purified from mitotic Xenopus egg 
extracts was shown to have higher ubiquitination activity than APC from interphase 
extracts, and APC in interphase extracts can be activated by adding Cdk1 [38-40]. The 
phosphorylation of APC by two serine/threonine kinases, protein kinase A (PKA) and 
Polo-like kinase (Plk1), play opposite roles in APC activation. PKA was shown to 
phosphorylate Apc1 and Apc3, which inhibits APC activity in vitro [41]. PKA can also 
phosphorylate Cdc20 when the DNA damage checkpoint is activated, and this 
phosphorylation prevents cell cycle progression until the damaged DNA has been 
successfully repaired [42]. Plk1 was shown to phosphorylate Apc1, Apc3, and Apc6 in 
mouse, which is dependent on active Cdk [41]. Cdc5, yeast homologue of Plk1, was 
shown to phosphorylate Cdc16 (yeast homologue of Apc6), Cdc27 (yeast homologue of 
Apc3), and Apc9, which is required for cyclin degradation in budding yeast [43]. Two 
mitotic cyclins, Clb1 and Clb2, are required for the transition from metaphase to 
anaphase in budding yeast, implying that Cdk1 activity is essential for APCCdc20 activation 
[44]. Recent study using structural and biochemical tools identified an auto-inhibitory 
segment of Apc1 which interacts with the C-box binding site to block activation of APC 
by Cdc20 [45-47]. Phosphorylation of this segment by Cdk1 displaces it from the C-box-
binding site thus activating APCCdc20 [45-47]. While Cdc20 preferentially binds to 
phosphorylated APC [43, 45-49], the association of APC to Cdh1 is prevented by the Cdk-
mediated phosphorylation on Cdh1, which is reversed by Cdc14 phosphatase to help 
trigger mitotic exit [49-51]. 11 putative Cdk sites exist on Cdh1 and allow it to be 
regulated by Cdk phosphorylation [49, 50, 52]. The mutant Cdh1 with all 11 Cdk putative 
phosphorylation sites replaced by alanine residues (Cdh1-m11) constitutively associates 







results in the failure of mitotic spindle formation, which finally leads to cell cycle arrest 
and cell death, highlighting the importance of regulating APC activity. Moreover, even 
the overexpression of wild-type Cdh1 can lead to mitotic arrest [54]. Besides affecting 
APC association, Cdk1 phosphorylation also promotes Cdh1 translocation from nucleus 
to cytosol, which prevents its access to many substrates [55, 56]. Besides Cdk1, Cdh1 is 
also phosphorylated by Cdc5, which is also critical for Cdh1 inactivation [57]. 
        Besides phosphorylation, co-activators are also commonly regulated by 
pseudosubstrates, which block substrate binding by competing for the same binding 
sites [35]. Many pseudosubstrates have been identified in diverse model systems, such 
as Emi1 in vertebrates [58], APCCdh1 modulator 1 (Acm1) in budding yeast [59], the 
mitotic checkpoint complex (MCC) in all eukaryotes [60], meiosis-specific protein 1 in 
fission yeast (Mes1) [61, 62], regulator of cyclin A 1 (Rca1) in Drosophila [63] , Mad2-like 
protein 2 (Mad2L2) in both human [64] and Xenopus [65], mitotic checkpoint factor 2 
(MCF2) in humans [66], and omission of second division 1 (OSD1) in plants [67]. The 
existence of pseudosubstrate inhibitors in diverse kingdoms of eukaryotic life suggests 
pseudosubstrates are an easily evolved and effective strategy to control APC activity. 
 
1.3.3 Contributions of APC to genome stability 
 
        Genomic instability is one of the most pervasive hallmarks of tumor cells and mainly 
results from unrepaired DNA damage [68]. Emerging evidence indicates APC plays a 
critical role in controlling genomic stability and tumor suppression [20, 69]. 
Downregulation of Cdh1 has been correlated with poor survival in glioma patients [70]. 
Heterozygous mice harboring a conditional knockout of Cdh1 have been shown to 
develop epithelial tumors [71]. Many proteins with strong relevance to cancer are 
substrates of the APC, including prominent mitotic kinases such as Plk1, Aurora kinases, 
and Cdk. The p53/p21 pathway is activated in Cdh1-depleted human cells which exhibit 
increased genomic instability [72]. Recently reported data implies it functions in the 







response to genotoxic stress in G2, Cdc14-activated APCCdh1 degrades Plk1, which results 
in the consequent stabilization of Claspin and Wee1 to arrest cells at the G2 checkpoint 
[70]. USP1, a critical regulator of DNA repair, is degraded in G1 by APCCdh1 in response to 
UV-induced DNA damage [74]. Thus, dampened APCCdh1 activity can result in the 
unscheduled accumulation of target proteins, which induces the failure of G2 
checkpoint and the consequent genome instability [70]. As Cdh1 plays critical roles in 
maintaining genomic stability by controlling cell cycle progression and checkpoints, its 
downregulation has been identified in many types of human cancers, such as murine B-
cell lymphoma cell line [75], human acute myeloid leukemia [72], human non-Hodgkin’s 
lymphoma [72], human acute lymphoblastic leukemia [72], human small-cell lung cancer 
[72], and breast, prostate, ovary, liver, and brain tumors [70]. As a key regulator in cell 
proliferation , APCCdh1 has been the subject of intense study.  However, how it functions 
to promote genomic stability by selectively targeting substrates in G1 phase is not 
completely understood. More APCCdh1 substrates may be involved in genome stability 
maintenance. Therefore, understanding the substrate recognition mechanism of APCCdh1 
will help identify more APCCdh1 substrates which may play critical roles in tumorigenesis. 
 
1.3.4 APC as a chemotherapeutic target 
 
        Interestingly, while Cdh1 functions as a tumor-suppressor playing a critical role in 
G1 maintenance and preventing premature S phase entry, Cdc20 was found to facilitate 
tumorigenesis by promoting mitotic progression [20, 69, 76]. In mitosis, genome 
stability is ensured by the spindle assembly checkpoint (SAC) which delays chromosome 
segregation until all sister chromatids have attached bidirectionally  to the mitotic 
spindle [77]. The SAC is imposed by MCC. Before the onset of anaphase, the activity of 
APCCdc20 is inhibited by MCC which is comprised of Mad2, BubR1, and Bub3 and is 
assembled and activated in the presence of unattached kinetochores [77]. After all 
kinetochores have successfully attached to the mitotic spindle, MCC gets disassembled 







hydrolyze cohesin to promote sister chromatid separation [77]. Therefore, Cdc20 
inhibition by MCC until proper chromosome attachment to the spindle is critical to avoid 
chromosome mis-segregation and aneuploidy which are hallmarks of cancer cells. 
        A class of widely-used clinical cancer drugs in the treatment of breast, ovarian, and 
lung cancer are microtubule inhibitors such as taxanes and the vinca alkaloids that block 
mitosis by preventing spindle formation or function [78]. However, the clinical efficacy 
of these drugs is variable due to the resistance of cancer cells to microtubule inhibition 
[79-81]. Since these drugs induce cell death by perturbing the mitotic spindle to induce 
SAC-dependent mitotic arrest and subsequent apoptosis, several groups have proposed 
that inhibitors directly targeting APCCdc20 might have better efficacy or at least represent 
alternative anti-mitotic strategies for cancer chemotherapy. Preclinical data showed 
that blocking mitotic exit by directly targeting APCCdc20 by either small molecule 
inhibitors or siRNA has a more potent cancer cell killing effect than the traditional 
spindle poisons [82-84]. Therefore, APC represents a potential novel target for cancer 
therapy [82-85]. 
        Since Cdc20 and Cdh1 have opposite effects on cell cycle progression and 
tumorigenesis, ideal clinical drugs should just inhibit the activity of APCCdc20 but not 
APCCdh1. However, because Cdc20 and Cdh1 share significant structural similarities, 
especially in their substrate binding domain, it is currently not possible to specifically 
inhibit one but not the other using available inhibitors. Moreover, the core APC is 
exactly the same for APCCdc20 and APCCdh1, so these two co-activators represent the only 
difference aside from cell cycle-specific post-translational modifications. Therefore, 
understanding substrate recognition by APC and how Cdc20 and Cdh1 recognize 















        APC recognizes its substrates via interacting with short motifs on substrates called 
degrons. Two common degrons have been well characterized on APC substrates: the 
destruction box (D-box), and KEN-box. D-box was originally identified in sea urchin cyclin 
B and found to have the consensus Arg-x-x-Leu-x-x-x-x-Asn [86, 87]. Functional D-boxes 
have been identified in many APC substrates [88], but a substantial number of APC 
substrates seem to lack canonical D-boxes [35]. The KEN-box, consisting of the 
consensus Lys-Glu-Asn sequence, was first identified as an alternative APC degron motif 
in human Cdc20 which lacks a conventional D-box [89]. KEN boxes have subsequently 
been found in many APC substrates as well. Besides D-box and KEN-box, several 
alternative degrons have been identified on various APC substrates that often lack 
consensus D- and KEN-boxes, such as GxEN in Xenopus Xkid [90], the A box in Xenopus 
Aurora A [91], the O-box in Drosophila ORC1 [92], LxExxxxN in S. cerevisiae Spo13 [93], 
LLK in human Claspin [94], the CRY-box in mouse Cdc20 [95], NKSEN in budding yeast 
Sgo1 [96], and the ABBA motif, Fx(I/V/L)(F/Y/H)x(D/E), in human Cyclin A, BubR1, and 
Bub1 [97, 98], and budding yeast Clb5 [99]. While some of these alternative degrons 
resemble the D- and KEN-boxes, such as the GxEN and NKSEN, many of these alternative 
degrons appear distinct from the canonical D- and KEN-boxes. Whether these non-
canonical degrons bind APC coactivators at the same binding sites as D- and KEN-boxes 
is largely unknown. Moreover, some substrates have extended regions with undefined 
degrons that have been identified as sufficient and/or necessary for their degradation, 
such as Iqg1 [100], Cik1 [101], and Kip1 [102] in budding yeast, and Usp1 in human [74]. 
Since a nuclear localization sequence (NLS) was also reported to be necessary for 
substrate degradation in budding yeast [101-104], some motifs required for degradation 








1.4.2 WD40 domain and degron receptors 
 
        APC substrates are recruited by the WD40 domain of both Cdc20 and Cdh1 (Figure 
1.5, 1.6, 1.7). Recent X-ray diffraction studies have revealed in high resolution detail 
how the D-box, KEN-box, and ABBA motif interact with the co-activator WD40 surfaces 
[60, 88]. The KEN-box receptor is situated on the top center of the 7-blade propeller-
shaped WD40 domain, while the D-box receptor is located in a channel between blades 
1 and 7 on the side of the propeller, and the ABBA motif receptor is on the bottom side 
of the propeller [60, 88]. The co-activator residues interacting with the degrons have 
been identified, mutations of which were shown to impair the APC-mediated 
ubiquitination of the substrates [60, 88]. In principle, these studies might be expected to 
provide clarity to our understanding of APC substrate recognition. However, several 
facts imply that our understanding of substrate recognition is far from complete. First, 
as noted above, many APC substrates have now been identified that contain neither D-
box, KEN-box, nor ABBA motifs. Second, many D-boxes contain only the core Arg-x-x-Leu 
sequence and this as well as the KEN sequence are found in many proteins that are 
clearly not APC substrates, indicating that additional factors must contribute to 
recognition of these degrons. Third, although Cdc20 and Cdh1 have very similar WD40 
domain structures with nearly identical D- and KEN-box binding sites, they do not 
recognize completely identical sets of substrates suggesting again that additional factors 
influence the ability of specific D- and KEN-box sequences to be recognized by co-
activators. Given the degeneracy in APC substrate degron motifs, it is unclear whether 
all APC substrates share common recognition determinants and if a universal 









Figure 1.5 Structure of WD 40 domain in Cdh1 
The structure of the complex of WD40 domain in Cdh1 (yellow) and Acm1 (pink) was 
made by JSmol using the protein information deposited in the Protein Data Bank under 









Figure 1.6 Cartoon of degron receptors on WD40 domain  
The KEN-box receptor is on the top center of the 7-blade propeller-shaped WD40 
domain, and the D-box receptor is in a channel between blades 1 and 7 on the side of 











Figure 1.7 Substrate recognition by WD40 domain 
WD40 domain on Cdc20 and Cdh1 is responsible for recognizing APC substrates via 
interacting with the APC degrons on substrates. The binding sites of D-box and KEN-box 
have been well identified, while it still remains unknown where other unconventional 

















1.4.3 Other determinants in substrate recruitment by APC 
 
        Besides the interaction between the degrons on substrates and the degron 
receptors on co-activators, some other interactions also contribute to substrate 
recruitment. NIMA-related kinase 2A (Nek2A) and Cyclin A can be targeted by 
alternative mechanisms, which allows them to be degraded in prometaphase, when 
MCC is active to block the degradation of the substrates using canonical degrons [105, 
106]. APC-mediated degradation of Nek2A in pro-metaphase depends on its exposed 
carboxy-terminal methionine–arginine (MR) dipeptide tail which allows Nek2A to bind 
APC directly instead of binding the degron receptors on Cdc20 [105]. Nek2A was shown 
to bind APC even in the absence of Cdc20 [105]. Different from Nek2A which can 
associate with APC independently of Cdc20, the degradation of cyclin A requires Cdc20, 
as well as Cks, a small Cdk accessory subunit  [106]. Cyclin A, Cdc20, and Cks form a 
complex even in the presence of Mad2 and the MCC to allow cyclin A to be degraded 
independently of the spindle checkpoint [106]. These data together suggest there could 
be diverse mechanisms of substrate recruitment, which is also revealed by the lack of a 
common degron motif in all APC substrates and the diversity of the known degrons.         
 
1.4.4 Pseudosubstrates – similarities to substrates and general properties 
 
        Besides substrates, APC can also recruit a set of proteins called pseudosubstrate 
inhibitors via its degron receptors. Pseudosubstrate inhibitors generally function by 
outcompeting substrates for binding to APC co-activators. Two features are believed to 
be required for a pseudosubstrate inhibitor: high affinity binding to outcompete true 
substrate in APC binding, and a way to avoid ubiquitination by APC when bound. 
However, it is still unclear in many cases what allows pseudosubstrates to evade 
ubiquitination and degradation. One possible mechanism is that the higher affinity of 
coactivator binding provided by additional docking motifs compared to real substrates 







APC are also identified in pseudosubstrates and are critical for their binding and 
inhibitory functions [58-60, 66, 107-109]. The degrons on pseudosubstrates display 
same sequences as the degrons on true substrates, which makes it difficult to 
understand what unique properties the degrons on pseudosubstrates have to recruit 
them to APC but prevent their degradation. The answer to this question will help us 
understand the APC substrate recognition mechanism better and possibly to design 
better APC inhibitors.  
        In contrast to many pseudosubstrate inhibitors, the mechanisms of APC inhibition 
by MCC and Emi1, have been intensively studied and characterized. MCC consists of 
Mad2, Mad3, Bub3, and Cdc20, and it directly binds to APC to inhibit its substrate 
recognition [60, 110]. The data from crystal structure of the fission yeast MCC showed 
that the KEN-box on Mad3 binds to the KEN-box receptor on Cdc20, which not only 
prevents Cdc20 from recognizing KEN-box on its substrates, but also displaces Cdc20 
toward Apc5 to disrupt the formation of the D-box receptor by both Cdc20 and Apc10 
[60]. Mad2 stabilizes MCC by optimally positioning the Mad3 KEN-box degron to bind 
Cdc20 [60]. A recent study of human MCC revealed that BUBR1 can use a D-box and the 
second KEN-box to bind a second Cdc20 molecule, which is required for SAC function 
[111]. However, it is still not understood why MCC is not degraded by APCCdc20 as a true 
substrate. Four functional elements of Emi1 are required for APCCdh1 inhibition by Emi1: 
D-box (Emi1D-box), zinc-binding region (Emi1ZBR), the linker connecting both Emi1D-box and 
Emi1ZBR (Emi1Linker), and C-terminal LRRL sequence (Emi1LR) [112-114]. Emi1D-box binds to 
the D-box co-receptor of Cdh1 and Apc10 to compete with real substrates for binding to 
APC [112-114]. Emi1Linker and Emi1ZBR together dock onto the UbcH10 binding site of 
Apc11 to block the association of UbcH10 and Apc11, which inhibits the transfer of 
ubiquitin from UbcH10 to the substrates [112-114]. Emi1LR is identical to the LRRL motif 
on ubiquitin-conjugating enzyme E2S (Ube2S), which allows it to block Ube2S 
association with APC [112-114]. Thus, Emi1 primarily acts by inhibiting E2 binding to the 
APC. However, other pseudosubstrates must act differently because they are 








1.5 APC regulation by Acm1 
 
1.5.1 Structure and function of Acm1 
 
        In budding yeast, Cdh1 is regulated by a pseudosubstrate inhibitor called Acm1 
(Figure 1.8). Acm1 was first identified as a stoichiometric interaction partner of Cdh1 by 
immuno-affinity purification and peptide mass fingerprinting in our lab [59]. Acm1 is a 
small protein of 23.8 kD that shows little sequence conservation other than Cdk1 
phosphorylation sites and APC-degron motifs and appears specific to fungi. The degron 
motifs include three D-boxes (two of them highly conserved), a KEN-box, and an ABBA 
motif. The Cdh1-Acm1 interaction is stable to 0.5 M salt, whereas Cdh1-substrate 
interactions are difficult to isolate even under physiological conditions, suggesting the 
Cdh1-Acm1 interaction is much stronger [59]. Acm1 was shown to inhibit the 
degradation of several substrates by competing for the degron binding sites on Cdh1 
[107, 109, 115]. A study using the dominant, constitutively active Cdh1-m11 mutant 
lacking inhibitory Cdk sites suggested that Acm1 functions as a physiological buffer to 
keep Cdh1 inactive in cooperation with Cdk1 [53]. Acm1 deletion results in cell defects 
in nuclear positioning and spindle morphology during mitosis, but not the 
destabilization of APCCdh1 substrates, which suggests that the major biological function 
of Acm1 is not to inhibit APCCdh1, but to prevent premature binding of Cdh1 to 
substrates where it could block their normal function [116]. For example, the bud neck-
localized kinase, Hsl1, was found to recruit Cdh1 inappropriately to the bud neck in the 
absence of Acm1, and this was responsible for the defect of acm1Δ cells in nuclear 
positioning during mitosis [116]. Acm1 interacts with the WD40 domain of Cdh1 via D-
box, KEN-box and ABBA motif, and these interactions are essential for normal inhibitory 
function (Figure 1.9) [59, 107-109]. The loss of these motifs strongly reduces binding to 
the Cdh1 WD40 domain as well as its ability to inhibit ubiquitination of substrates that 







contain either D-box or KEN-box, it is unknown if Acm1 can also inhibit the degradation 



























Figure 1.8 Acm1, an APCCdh1 pseudosubstrate, inhibits the degradation of APCCdh1 
substrates via competing for the same binding sites. 
Acm1 is a pseudosubstrate of APCCdh1. It competes with true APCCdh1 substrates for 
binding APCCdh1 at the same binding sites. Acm1 binds APCCdh1 with much higher affinity 
than true APCCdh1 substrates, which is required for its inhibitory function. However, 
Acm1 does not get targeted for degradation by APCCdh1. The mechanism by which it 

















Figure 1.9 Acm1 has several APC degron motifs to inhibit the degradation of APCCdh1 
substrates via competing for the same binding sites. 
Acm1 has a compact structure. Several APC degrons have been identified on its central 
inhibitory region which is responsible for APCCdh1 inhibition: a D-box, a KEN-box, an 
ABBA motif, and a NEN-motif which was shown to bind KEN-box receptor on WD40 
domain on Cdh1 in vitro. ABBA motif, D-box as well as KEN-box were shown important 























1.5.2 Regulation of Acm1 
 
        Acm1 protein level is tightly regulated during the cell cycle, rising in late G1 when it 
functions as an APC inhibitor, and declining in mitosis [59, 107-109, 117]. It is stabilized 
by Cdk1 phosphorylation, and destabilized by Cdc14 phosphatase-mediated 
dephosphorylation [107, 117, 118]. This ensures that Cdh1’s inhibitor is stably expressed 
at the same time that Cdk1 is actively inhibiting the APC-Cdh1 interaction. Following 
dephosphorylation by Cdc14 in anaphase, APCCdc20 recognizes a conserved N-terminal D-
box in Acm1, targeting a fraction of Acm1 for degradation to help relieve inhibition of 
Cdh1 (Figure 1.8) [109]. However, APCCdc20 does not fully degrade Acm1. In fact, APCCdc20 
is neither necessary nor sufficient for complete degradation of Acm1 during mitotic exit 
[117]. An unconventional cell cycle-regulated, APC-independent, but 26S proteasome-
dependent proteolytic mechanism is responsible for Acm1 clearance in late mitosis and 
G1 phase [119]. Interestingly, neither lysine residues on Acm1 nor assembly of 
polyubiquitin chains are required for the degradation of Acm1 by this mechanism [119], 
suggesting that it is mechanistically unique. 
 
1.5.3 Acm1 used as a tool 
 
        Pseudosubstrates have been instrumental in providing structural insight into 
recognition of the D-box, KEN-box, and ABBA motif by Cdc20 and Cdh1. For example, 
structural studies using MCC, Emi1 and Acm1 have provided important information 
about recognition of APC degrons by both APCCdc20 and APCCdh1 [25, 60, 88]. Acm1 has 
been shown to inhibit the proteolysis of several conventional D- and KEN-box substrates, 
such as the cyclin B ortholog Clb2, the budding yeast securin Pds1, and the kinase Hsl1 
[59, 107-109, 117], however, it is unknown if Acm1 is a universal inhibitor of APCCdh1. 
Importantly, it is unknown if Acm1 can inhibit the degradation of APCCdh1 substrates 
lacking D- and KEN-boxes and containing unconventional degrons. The answer would 







common mechanism is employed. Moreover, since Acm1 can be degraded by APCCdc20 
as a true substrate but functions as a pseudosubstrate inhibitor of APCCdh1, 
understanding the underlying mechanism of the different roles Acm1 plays in 
interacting with APCCdc20 and APCCdh1 can help understand how APCCdc20 and APCCdh1 
recognize substrates, especially the degrons, differently. Why is Cdc20 not inhibited by 
Acm1’s central region and why does Cdh1 not recognize the N-terminal D-box to 
promote Acm1 degradation? Because the degrons on Acm1 have the same consensus 
sequences as those on true substrates, it is critical to understand what unique 
properties the degrons of Acm1 might have to help Acm1 avoid degradation and 
facilitate its inhibitory properties. The answers to these questions will help us 
understand what the mechanisms and determinants of substrate recognition by APC, 
what distinguishes a substrate from a pseudosubstrate inhibitor, and how we might 






















CHAPTER 2. MATERIALS AND METHODS 
 
2.1 Reagents and antibodies 
 
        Reagents and antibodies were obtained from commercial sources: Cycloheximide 
(C1988), 3×FLAG peptide (F4799), rabbit polyclonal anti-Protein A (P3775), mouse 
monoclonal anti-FLAG-M2 (F1804) and rabbit polyclonal anti-G6PDH (A9521) were from 
Sigma-Aldrich. SYTOX Green nucleic acid stain (S7020) was from Thermo Fisher Scientific. 
XbaI (R0145S), XhoI (R0146S), Spe1 (R0133S), and T4 ligase (M0202S) were from NEB. 
Luminata Crescendo Western HRP substrate (WBLUR0100) was from Millipore. Anti-
FLAG resin (L00432) was purchased, and α-factor peptide was synthesized and purified 
from Genscript. Rabbit polyclonal Clb2 (SC9071) was from Santa Cruz Biotechnology. 
Horseradish peroxidase-conjugated anti-rabbit (#111-035-003) and anti-mouse (#115-
035-003) secondary antibodies used were from Jackson ImmunoResearch. Rabbit 
polyclonal anti-Acm1 antibody was made in our lab as described before [119]. APC1 and 





        All plasmids used in this study are listed in Table 2.1. All plasmids constructed using 
PCR were confirmed by DNA sequencing. The plasmids with BG1805 backbone 
expressing APC substrates with C-terminal protein A tags are from Yeast ORF Collection 
(GE, YSC3868). The plasmids expressing ASE1-TAP, SPO12-TAP, SPO13-TAP, and Hsl1667-







were constructed by amplifying the genes by PCR from yeast genomic DNA (BY4741 
strain) and then inserting the products into the entry vector using Gateway Entry system 
from Life Technologies (pENTR/D-TOPO Cloning Kit, K240020) and then transferred into 
destination vectors pAG-416Gal-ccdB-TAP from S. cerevisiae Advanced Gateway 
Destination Vectors Library (Addgene, Kit# 1000000011) [120]. pHLP523 was 
constructed by removing ΔN52 Acm1 from pHLP400 described previously [119] and then 
inserting into p415MET. XbaI and XhoI were used to cut both pHLP400 and p415MET 
plasmids. The ligation was performed by using T4 ligase. pHIP032 and pHLP042 were 



























Table 2.1 Plasmid constructs 
 
Name Type Marker Promoter Expressed Protein Source 
BG1805-Clb2 2 micron URA3 GAL1 Clb2-6His/HA/3C/ZZ GE 
BG1805-Cin8 2 micron URA3 GAL1 Cin8-6His/HA/3C/ZZ GE 
BG1805-Cik1 2 micron URA3 GAL1 Cik1-6His/HA/3C/ZZ GE 
BG1805-Fin1 2 micron URA3 GAL1 Fin1-6His/HA/3C/ZZ GE 
BG1805-Kip1 2 micron URA3 GAL1 Kip1-6His/HA/3C/ZZ GE 
BG1805-Pds1 2 micron URA3 GAL1 Pds1-6His/HA/3C/ZZ GE 
BG1805-Mps1 2 micron URA3 GAL1 Mps1-6His/HA/3C/ZZ GE 
BG1805-Iqg1 2 micron URA3 GAL1 Iqg1-6His/HA/3C/ZZ GE 
BG1805-Sgo1 2 micron URA3 GAL1 Sgo1-6His/HA/3C/ZZ GE 
BG1805-Cdc5 2 micron URA3 GAL1 Cdc5-6His/HA/3C/ZZ GE 
BG1805-Ipl1 2 micron URA3 GAL1 Ipl1-6His/HA/3C/ZZ GE 
BG1805-Swe1 2 micron URA3 GAL1 Swe1-6His/HA/3C/ZZ GE 
BG1805-Nrm1 2 micron URA3 GAL1 Nrm-6His/HA/3C/ZZ GE 
BG1805-Cdc20 2 micron URA3 GAL1 Cdc20-
6His/HA/3C/ZZ 
GE 
pHLP520 CEN/ARS URA3 GAL1 Ase1-TAP This study 
pHLP521 CEN/ARS URA3 GAL1 Spo12-TAP This study 
pHLP522 CEN/ARS URA3 GAL1 Spo13-TAP This study 
pHLP400 CEN/ARS LEU2 GAL1 Acm1∆52-ZZ [119] 
pHLP523 CEN/ARS LEU2 MET25 Acm1∆52-ZZ This study 
pHLP525 CEN/ARS LEU2 GAL1 Acm1db∆52-ZZ This study 
pHLP526 CEN/ARS LEU2 GAL1 Acm1kb∆52-ZZ This study 
pHLP527 CEN/ARS LEU2 GAL1 Acm1am∆52-ZZ This study 
pHLP528 CEN/ARS LEU2 GAL1 Acm1nen∆52-ZZ This study 







Table 2.1 continued 
 
pHLP530 CEN/ARS LEU2 GAL1  Acm1db,kb∆52-ZZ This study 
pHLP533 CEN/ARS LEU2 GAL1 Acm1db,am∆52-ZZ This study 
pHLP537 CEN/ARS LEU2 GAL1 Acm1db,nen∆52-ZZ This study 
pHLP538 CEN/ARS LEU2 GAL1 Acm1db,kb,am∆52-ZZ This study 
pHLP546 2 micron URA3 GAL1 Cdc20de1-
6His/HA/3C/ZZ 
This study 
pHLP547 2 micron URA3 GAL1 Pds1de-
6His/HA/3C/ZZ 
This study 
pHLP317 2 micron LEU2 GAL1 Fin1-HA This study 
pHLP548 2 micron LEU2 GAL1 Fin1de-HA This study 
pHLP549 2 micron LEU2 GAL1 Fin1deA-HA This study 
pHLP550 2 micron LEU2 GAL1 Fin1deAf3-HA This study 
pHLP551 2 micron LEU2 GAL1 Fin1deAl4-HA This study 
pHLP553 CEN/ARS URA3 GAL1 Hsl1667-872-TAP This study 
pHLP554 CEN/ARS URA3 GAL1 Hsl1667-872de-TAP This study 
pHLP555 CEN/ARS URA3 GAL1 Hsl1667-872 def3-TAP This study 
pHLP556 CEN/ARS URA3 GAL1 Hsl1667-872 del3-TAP This study 
pHLP557 CEN/ARS LEU2 GAL1 Acm1de∆52-ZZ This study 
pHLP558 CEN/ARS LEU2 GAL1 Acm1def3∆52-ZZ This study 
pHLP559 CEN/ARS LEU2 GAL1 Acm1del3∆52-ZZ This study 
pHLP560 CEN/ARS LEU2 GAL1 Acm1deD∆52-ZZ This study 
pHLP561 CEN/ARS LEU2 GAL1 Acm1deE∆52-ZZ This study 
pHLP562 CEN/ARS LEU2 GAL1 Acm1deF∆52-ZZ This study 
pHLP563 CEN/ARS LEU2 GAL1 Acm1deA∆52-ZZ This study 
pHLP564 CEN/ARS LEU2 GAL1 Acm1deAf3∆52-ZZ This study 







Table 2.1 continued 
 
pHLP164 2 micron HIS3 GAL1 3FLAG-Cdh1CT(241-
566) 
[115] 
pHLP276 CEN/ARS URA3 GAL1 3FLAG-Cdh1-m11 [59] 
pHIP032 Integrating HIS3 CDH1 3Flag-Cdh1 [116] 
pHIP042 Integrating HIS3 CDH1 3Flag-Cdh1dbr [116] 
pHIP174 Integrating HIS3 CDH1 3Flag-Cdh1kbr This study 
pHIP175 Integrating HIS3 CDH1 3Flag-Cdh1amr1 This study 
pHIP176 Integrating HIS3 CDH1 3Flag-Cdh1amr2 This study 
 
ZZ is a domain of Protein A 
3C represents the protease 3C cleavage site 





















2.3 Site-directed mutagenesis 
 
All site-directed mutagenesis was performed using the QuikChange Lightning 
Multi Site-Directed Mutagenesis Kit (Agilent Technologies, 210515). All plasmids were 































Table 2.2 Site-directed mutant plasmids 
 
Plasmid Sequence of mutation (5’-3’) Position of mutation 
pHIP042 L255V, P258A, G535A, and D536A D-box receptor on Cdh1 [108] 
pHIP174 N405A, N407A, Q473A, R517L KEN-box receptor on Cdh1 [60] 
pHIP175 I311S, K333T ABBA motif receptor on Cdh1[88]  
pHIP176 I311S, K333T, L325N, I344G, P374K ABBA motif receptor on Cdh1[88] 
pHLP525 R119A, L122A D-box on Acm1 
pHLP526 K98EN to AAA KEN-box on Acm1 
pHLP527 F61MLYEE to AMAAQQ ABBA motif on Acm1 
pHLP528 N90EN to AAA NEN-motif on Acm1  
pHLP529 K196A, R199A, K200A K-motif on Acm1 
pHLP530 R119A, L122A, and K98EN to AAA D-box/KEN-box 
pHLP533 R119A, L122A, and F61MLYEE to 
AMAAQQ 
D-box/ABBA motif 
pHLP537 R119A, L122A, and N90EN to AAA D-box/NEN-motif 
pHLP538 R119A, L122A, K98EN to AAA, and 
F61MLYEE to AMAAQQ 
D-box/KEN-box/ABBA-motif 
pHLP546 T26KLNILS to DEFKGYI D-box extension (DBE) on Cdc20 
pHLP547 N94RSKSFI to DEFKGYI DBE on Pds1 
pHLP548 T16IGRNNI to DEFKGYI DBE on Fin1 
pHLP549 T16IGRNNI to AAAAAAA DBE on Fin1 
pHLP550 T16IG to AAA DBE on Fin1 
pHLP551 R19NNI to AAAA DBE on Fin1 
pHLP554 S837FNKMNK to DEFKGYI DBE on Hsl1 
pHLP555 S837FN to DEF DBE on Hsl1 
pHLP556 M841NK to GYI DBE on Hsl1 







Table 2.2 continued 
 
pHLP558 D128EF to SFN DBE on Acm1 
pHLP559 G132YI to MNK DBE on Acm1 
pHLP560 D128 to S DBE on Acm1 
pHLP561 E129 to F DBE on Acm1 
pHLP562 F130 to N DBE on Acm1 
pHLP563 D128EFKGYI to AAAAAAA DBE on Acm1 
pHLP564 D128EF to AAA DBE on Acm1 
pHLP565 K131GYI to AAAA DBE on Acm1 
























Table 2.3 Primers for gene cloning and mutagenesis 
 

























amplify Ase1 from genomic DNA 
TOPOASE1-
REVERSE 
AATATCTGTAAAGGAGAATCCATTC amplify Ase1 from genomic DNA 
Fin1 topo F CACCATGAGCAATAAAAGCAACCG
C 
amplify Fin1 from genomic DNA 
Fin1 topo R CTTATGTTTCGGTATTTCCG amplify Fin1 from genomic DNA 
Hsl1 topoF CACCATGCAAAACTCGGCTTCAAAG
AGATCC 
amplify HSL1 fragment encoding 
aa 667-872 from genomic DNA 
Hsl1 topoR CTGAATAGGTTTGAGTGGTGACG amplify HSL1 fragment encoding 





mutate KEN-receptor on Cdh1 





















































mutate ABBA-motif on Acm1 
(F61MLYEE to AMAAQQ) 
AR GTTTCTTTCTTCAGCCGTTTGCTGAG
CCGCCATAGCTTGTGCAGCTTTAG 
mutate ABBA-motif on Acm1 






mutate NEN-motif on Acm1 (N90EN 





mutate NEN-motif on Acm1 (N90EN 
to AAA) based on wt Acm1 
KF CCGATGACGTCAGTGAAAAAGCAGT
AGTGGCAGCACTGTCCTTCCACGTC 












mutate D-box extension region 
















mutate D-box extension 
region (S837FNKMNK) on 






mutate D-box extension 
region (D128EF) on Acm1 to 






mutate D-box extension 
region (G132YI) on Acm1 to 





mutate D-box extension 
region (D128) on Acm1 to 





mutate D-box extension 
region (E129) on Acm1 to that 





mutate D-box extension 
region (F130) on Acm1 to that 






mutate D-box extension 
region (S837FN) on Hsl1 to 






mutate D-box extension 
region (M841NK) on Hsl1 to 
















mutate D-box extension region 








mutate D-box extension region 








mutate the first D-box extension 
region (T26KLNILS) on Cdc20 to that 






mutate D-box extension region 






mutate D-box extension region 






mutate D-box extension region 






mutate D-box extension region 






mutate D-box extension region 
















mutate D-box extension region 































        All yeast strains used in this study are listed in Table 2.2. YKA412 was generated by 
standard PCR-mediated deletion of the entire CDH1 coding region with the KanMX4 
cassette. YKA627, YKA628, YKA897, YKA898, and YKA1006 were constructed by 
integrating plasmids expressing wild-type Cdh1 or mutant Cdh1 with D-box, KEN-box, or 
ABBA motif receptor mutations (pHIP032, pHIP042, pHIP174, pHIP175, and pHIP176) 
from the natural CDH1 promoter respectively into the his3Δ0 locus of parental strain 



























Table 2.4 Yeast strains 
 
Strain Name Relevant Genotype Source 
YKA233 bar1::hisG [59] 
YKA412 bar1::hisG cdh1::KanMX4  This study 
YKA627 bar1::hisG cdh1::KanMX4 his3::3xFLAG-CDH1:HIS3 This study 
YKA628 bar1::hisG cdh1::KanMX4 his3::3xFLAG-cdh1dbr:HIS3 This study 
YKA897 bar1::hisG cdh1::KanMX4 his3::3xFLAG-cdh1kbr:HIS3 This study 
YKA898 bar1::hisG cdh1::KanMX4 his3::3xFLAG-cdh1amr1:HIS3 This study 
YKA1006 bar1::hisG cdh1::KanMX4 his3::3xFLAG-cdh1amr2:HIS3 This study 
YKA247 bar1::URA3 acm1::KanMX4 [59] 
YKA407 bar1::hisG acm1::KanMX4 pdr5::URA3 [117] 
BY4741apc10D apc10::KanMX4 [121] 
 
All the strains in Table 2.2 are derived from BY4741: MATa his3Δ1 leu2Δ0 met15Δ0 



















2.5 Cell growth 
 
        YP medium contained 1% yeast extract, 2% peptone, and 2% carbon source (either 
glucose, raffinose, or galactose). Synthetic dropout (SD) medium contained 6.7 g/L yeast 
nitrogen base, amino acid supplement mixture, and 2% carbon source (either glucose, 
raffinose, or galactose). All yeast liquid cultures were grown at 30 °C with shaking at 225 
rpm.  
 
2.6 In vivo protein stability assay 
 
        Yeast harboring expression plasmids for Acm1∆52-Protein A and/or APC substrates 
were cultured in the appropriate SD medium overnight until saturated, and then diluted 
to OD600 ≈0.1 in YP with 2% raffinose and allowed to grow until OD600 ≈0.2-0.3. Then the 
cells were treated with α-factor (100µg/L for bar1∆ strains and 10mg/L for BAR1 strains) 
for 2.5-3h to ensure most cells were arrested in G1 phase (checked by microscopy). For 
Acm1 inhibition assay, cells were pelleted by centrifugation at 5,000×g for 3 min and 
then washed with 10ml H2O and pelleted again. Cells were resuspended in SD raffinose 
medium without methionine and containing α-factor (100µg/L for bar1∆ strains) to 
induce the expression of Acm1. After 0.5h induction, galactose was added to 2% to 
induce the expression of APC substrates. Glucose and cycloheximide were added to stop 
both transcription and translation after 45min induction. For assays other than Acm1 
inhibition assay, the media was not changed and galactose was added directly to 2% to 
induce expression of APC substrates. Glucose and cycloheximide were then added after 
45min. Cell aliquots (10ml) were harvested at regular intervals, collected by 
centrifugation, washed with 10% TCA, and frozen until processing for immunoblotting. 












Figure 2.1 Flowchart for the in vivo substrate stability assay. 
The methionine-repressible Acm1Δ52 expression is only relevant to the assay in which 
substrate stability were compared in the presence and absence of Acm1. Control cells 
lacked the Acm1Δ52 expression plasmid to establish basal instability of substrates. CHX, 


























2.7 Trichloroacetic acid (TCA) protein extraction 
 
        Yeast cells were collected by centrifugation and then immediately resuspended in 1 
ml ice-cold 20% TCA and transferred to a 1.5 ml microtube. Cells were then pelleted 
again by centrifugation and resuspended in 250 µl ice-cold 20% TCA. 250 µl acid-washed 
0.5 mm glass beads (Biospec Products, 11079105) were added to disrupt cells by using 
Vortex-Genie 2 Vortex Mixer (G4788253) from Scientific Industries, Inc. for 10 minutes 
at 4˚C. The cell lysate was transferred to new microfuge tube. The glass beads were 
washed with 750 µl 5% TCA, and the liquid was combined with the 250 µl cell lysate. The 
protein was pelleted by centrifugation in a microfuge at 16100xg for 10 min, and the 
supernatant was discarded. The pellet was washed with 1 ml ice-cold ethanol and 
pelleted again by centrifugation at 16100xg for 5 min. The supernatant was discarded, 
and the pellet was dried in air. The pellet was resuspended in SDS Loading dye at 20 µl 
per 1x107 cells. The number of cells was determined by conversion from OD600 
absorbance reading before the cells were harvested. OD600 of 0.1 is approximately equal 
to 1-2x106 cells/ml [122]. The sample was boiled at 95˚C for 10 minutes, and sonicated 
briefly. Then the sample was centrifuged at 16100xg for 10 minutes, and the 
supernatant was transferred to a fresh microfuge tube. 
 
2.8 Western blot 
 
        The protein extracts generated from TCA pellets as described above were loaded on 
SDS-PAGE gel containing appropriate percentage of acrylamide to separate the proteins 
using standard Tris-glycine buffer system. The samples were running under constant 
voltage of 180 V until the targeted proteins reached the appropriate positions. During 
the last 5 minutes of SDS-PAGE gel separation, the following materials were prepared 
for protein transfer: 2 pieces of filter paper and 2 sponges pre-wet in transfer buffer (25 
mM Tris pH 8.3-8.5, 192 mM Glycine), PVDF membrane pre-wet in methanol, and 







gel running is completed, the transfer sandwich cassette (filter paper-gel-membrane-
filter paper) was assembled. The proteins were transferred from gel to PVDF membrane 
in transfer buffer at 350 mA for 1 hour with continuous mixing by stir bar. Then the 
membrane was incubated in PBST (136 mM NaCl, 2.7 mM KCl, 18.9 mM Na2HPO4, 1.8 
mM KH2PO4, 0.1% Tween-20, pH 7.0-7.5) containing 5% non-fat dry milk for 1h at room 
temperature (or 4°C overnight) to block non-specific binding sites. Then the blocking 
solution was dumped off and the membrane was incubated with 15 ml PBST containing 
primary antibody at the appropriate dilution (see below) on a rocker at room 
temperature for 30 min except anti-APC1, anti-Cdc23, and anti-FLAG-M2 antibody which 
requires overnight incubation at 4°C. The membrane was washed 3x10 minutes with 
PBST and then incubated with 15 ml PBST containing secondary antibody at the 
appropriate dilution on a rocker at room temperature for 20 min (2 h for anti-FLAG-M2 
antibody). Then the membrane was washed again 3x10 minutes with PBST and 
incubated with Luminata Crescendo Western HRP substrate from Millipore at room 
temperature for 5 min. The blot signals were detected either on film (BX57 from Midsci) 
or digital imager (ChemiDoc Touch from Bio-Rad). The signals obtained by film were 
quantified using ImageJ software. The signals obtained by digital imager were quantified 
using Image Lab software (Bio-Rad). The band intensities were normalized to the G6PDH 
loading control first and then to the first time point to create degradation profile of each 
protein.  
        Antibodies were diluted according to the instructions: Acm1 (1:10000), Protein A 
(1:10000), Clb2 (1:3000), Flag M2 (1:2000), G6PDH (1:5000), APC1 (1:3000), Cdc23 




        For co-IP analysis of Cdh1 interaction with core APC, YKA412, YKA627, YKA628, 
YKA897, and YKA1006 were cultured overnight in 5 ml SD-His selective medium and 







arrested in G1 with α-factor. For co-IP analysis of Cdh1 interaction with Acm1, YKA412, 
YKA628, and YKA897 were cultured overnight in 5 ml SD-His selective medium then 
back-diluted into 500 ml SD-His selective medium and grown to OD600 ≈ 0.6 without G1 
arrest. For co-IP analysis of C terminus of Cdh1 (Cdh1CT) interaction with both Fin1 and 
Acm1, YKA247 transformed with both pHLP164 and the plasmids expressing either 
different alleles of Fin1 (pHLP317, pHLP548, and pHLP549) or different alleles of Acm1 
(pHLP400, pHLP525, pHLP557, and pHLP563) were cultured overnight in 5 ml SD-His/Leu 
selective medium and then back-diluted in 300ml YP+raffinose medium and grown to 
OD600 ≈ 0.3 and arrested in G1 with α-factor. Then both Cdh1CT and Fin1 or Acm1 
expression were induced by adding galactose to 2% final concentration. The induction 
took about 45 min. The cells were pelleted and washed once with H2O, and then 
pelleted again. The cell pellets were resuspended in 10 volumes of buffer L (25 mM 
HEPES pH 7.5, 100 mM sodium acetate (400 mM for co-IP analysis of Cdh1CT with 
Acm1), 10% glycerol, 0.1% Triton X-100, 0.5 mM dithiothreitol) supplemented with 1 
mM phenylmethylsulfonyl fluoride, 1 µM pepstatin, 100 µM leupeptin, and 5 mM EDTA, 
and then distributed into 1.5 ml microcentrifuge tubes (maximum 900 µl per tube). 
About 200 µl acid-washed 0.5 mm glass beads (Biospec Products, 11079105) were 
added to each tube, and cells were agitated in a Disruptor Genie (Scientific Industries) at 
4°C until greater than 75% of the cells were lysed (3 times agitation with 5 min interval 
to cool down the cells, 10 min each time). Then the supernatant of each tube are 
collected, pooled, and cleared by centrifugation at 16,000×g for 30 min. Then 20 µl total 
anti-FLAG resin (equilibrated first in Buffer L) was added to the supernatant and 
incubated on a rotating platform for 2 h at 4°C. Then the resin was washed with 10 ml 
buffer L in a 15 ml conical tube (4 times and 5min each time) and then transferred to a 
1.7 ml Axygen low-bind microtube. The resin was then washed twice more with 1 ml 
buffer L. The bound protein was eluted twice by incubating with 200 µg/ml 3FLAG 
peptide in 40 µl buffer L on a rotating platform for 20 min at room temperature. It is 







elution, 4×SDS loading day was added to 1×, and the sample heated for 10 min at 95°C 
for subsequent analysis by Western blot.  
 
2.10 Flow cytometry 
 
        500 µl yeast cell culture were transferred to a microfuge tube and pelleted by 
centrifugation at 5,000 rpm for 1 min.  The cell pellet was washed with 1 ml ddH2O and 
pelleted again by centrifugation at 5,000 rpm for 1 min.  Then the cells were fixed by 1 
ml cold 70% ethanol for at least 30 min (can be left overnight at 4°C). The cells were 
pelleted by centrifugation at 5,000 rpm for 1 min and then washed with 1 ml 
ddH2O.  Then the cells were pelleted by centrifugation again at 10,000xg for 2 min, and 
H2O was discarded. The cell pellet was resuspended in 500 µl 1 mg/ml RNase A in 50 
mM Tris-HCl pH 8.0 and 15 mM NaCl, and incubated at 37°C for at least 2 hours. The 
cells were pelleted by centrifugation at 10,000xg for 2 min to remove RNase solution. 
Then the cell pellet was resuspended in 250 µl 5 mg/ml pepsin solution and incubated at 
37°C for exactly 30 min.  The cells were pelleted by centrifugation again at 10,000xg for 
2 min to remove pepsin solution, and then washed with 1 ml 50 mM Tris-HCl pH 8.  Then 
the cells were pelleted by centrifugation again at 10,000xg for 2 min to remove wash 
solution. The cells then were resuspended in 1 ml 1 µM SYTOX green in 50 mM Tris-HCl 
pH 8 and stored at 4°C until flow cytometry analysis. The samples were sonicated on 
amplitude setting of 30 for 10 seconds to disrupt cell clumps immediately prior to 
analysis by flow cytometry using Accuri C6 flow cytometer. 10000 cells were collected at 
high fluidics rate, and filter FL1 was used. 
 
2.11 In vivo inhibition spotting assay 
 
        Liquid yeast cultures were grown in SD selective media overnight to saturation. The 
saturated cultures were diluted with ddH2O to make five 5-fold serial dilutions. 5 µl each 







galactose as the carbon source. After 2 days growth (4 days for YP+galactose), plates 
































CHAPTER 3. SUBSTRATE RECOGNITION BY THE CDH1 DESTRUCTION BOX RECEPTOR IS 




        The anaphase-promoting complex, or cyclosome (APC/C), polyubiquitylates 
numerous cell cycle regulatory proteins to target them for proteasomal degradation. In 
doing so, the APC/C triggers anaphase chromosome segregation, the inactivation of 
cyclin-dependent kinases and other mitotic kinases, cytokinesis, and establishment of a 
stable G1 state [123-125]. Proper coordination of late mitotic events by the APC/C is 
critical for faithful genome transmission during cell division [69, 71, 72]. How the APC/C 
selectively targets the appropriate substrates at the correct time to orchestrate cell 
cycle events is an important question and active area of investigation [22, 35, 125, 126].  
        The APC/C coactivators Cdc20 and Cdh1 contribute to substrate recognition via 
docking sites on their conserved WD40 repeat domains [35, 126]. Two substrate degron 
motifs that bind distinct sites shared by both coactivators have been characterized in 
detail. The destruction box (D-box), originally identified in sea urchin cyclin B and 
subsequently found in many other APC/C substrates, has the consensus sequence 
RxxLxx(I/V/L)xN but is often found with alternative amino acids at the I/V/L and N 
positions [86-88]. The KEN-box was first identified as an APC/C degron in human Cdc20 
[89] and has since been found in many other APC/C substrates [35]. The location and 
structure of the D-box and KEN-box binding sites on Cdh1 and Cdc20 were recently 
revealed through X-ray diffraction and high resolution cryo-electron microscopy studies, 
providing detailed views of how common degrons are recognized by APC/C coactivators 







        Despite these significant recent advances, our overall understanding of APC/C 
substrate recognition determinants is still incomplete. While mutation of D- and KEN-
box degrons stabilizes substrates in vivo, these motifs are often not sufficient for 
degradation, suggesting that other sequence elements are important as well [35, 87].        
        Moreover, the RxxL and KEN consensus sequences are found frequently in proteins 
that are not APC/C substrates and thus must exist in an appropriate structural context 
to function as degrons. Some APC/C substrates contain both D- and KEN-boxes while 
others appear to contain only one or the other, and there are now many examples of 
substrates that lack functional consensus sequences for both [35, 126]. The source of 
binding specificity and affinity in substrates lacking one or both canonical degron motifs 
remains unknown in most cases. Finally, although Cdc20 and Cdh1 have very similar 
WD40 domain structures with nearly identical D- and KEN-box binding sites [60, 88], 
they recognize distinct sets of substrates, suggesting again that additional factors 
influence specificity [128].  
        Many alternative APC/C degrons have been identified, often in substrates lacking 
consensus D- or KEN-boxes. These include GxEN in Xenopus Xkid [90], the A box or DAD 
motif (RxLxPSN) in Xenopus Aurora A [91, 129], the O-box (PASPLTEKNAK, essential 
residues underlined) in Drosophila ORC1 [92], LxExxxxN in S. cerevisiae Spo13 [93], L-L-K 
in human Claspin [94], the CRY-box in mouse Cdc20 [95], NKSEN in budding yeast Sgo1 
[96], and the ABBA motif, Fx(I/V/L)(F/Y/H)x(D/E), in human Cyclin A, Bub1, and budding 
yeast Clb5 [97, 99]. Only the ABBA motif has a known binding site on the coactivator 
WD40 domains [88, 98]. Some alternative degrons resemble D- and KEN-boxes, 
including RQLF in budding yeast Ase1 [130] and GxEN and NKSEN in XKid and Sgo1, 
respectively. Furthermore, a KxxL sequence in budding yeast Cin8, the LxExxxxN degron 
in Spo13, and the Orc1 O-box can bind the D-box docking site on Cdh1 to some extent 
and XKid’s GxEN can similarly bind the KEN-box receptor site [88], suggesting that they 
are functional variants of these consensus degrons. Many of the alternative sequences 
though, appear distinct from the canonical D- and KEN-box degrons. Where they bind 







largely unknown. Some substrates still have undefined degrons, including several (e.g. 
budding yeast Iqg1 [100], Cik1 [101], and Kip1 [102], and human Usp1 [74]) for which 
extended regions have been identified as sufficient and/or necessary for degradation 
but that lack consensus D- and KEN-box motifs. Nuclear localization also appears to be 
required for degradation of APC/C substrates in budding yeast [103] and therefore some 
degrons may act by promoting nuclear import and not by binding the APC/C or its 
coactivators.  
        The lack of a common degron in all APC/C substrates and the diversity of reported 
degrons raise the question of whether any universal determinants of substrate 
recognition exist. One explanation for the diversity in substrate degrons is that different 
substrate classes bind independent sites on the coactivators and/or core APC/C. If so, 
this would provide a potential mechanism for differential regulation of substrate binding 
and processing. There is some precedent for this idea. The Cdc20 targets cyclin A and 
Nek2A have alternative mechanisms for recognition by APC/C, allowing them to be 
degraded in prometaphase when the mitotic checkpoint complex is active and blocks 
degradation of securin and cyclin B, which rely on canonical degrons [105, 106]. Here, 
we used an in vivo substrate degradation assay in budding yeast to test for distinct 
substrate recognition modes for the Cdh1 coactivator and to explore the relative 
contributions of the known degron binding sites to Cdh1 substrate proteolysis. Our 
results argue against completely independent substrate binding modes and suggest that 
most, if not all, Cdh1 substrates require a functional D-box receptor on APC/CCdh1 for 




3.2.1 Acm1 inhibits proteolysis of diverse Cdh1 substrates 
 
        The Acm1 protein is a pseudosubstrate inhibitor of APC/CCdh1 that acts by 







motifs and the recently identified ABBA motif (originally called the A-motif in Acm1) 
[107, 109, 115]. Acm1 has only been shown to inhibit the ubiquitylation and degradation 
of a small number of classical APC/CCdh1 substrates that contain well-defined KEN- 
and/or D-box degrons [88, 107-109, 115]. It remains unclear if Acm1 can also inhibit 
degradation of substrates with non-canonical degrons that lack consensus KEN- and/or 
D-box motifs. To answer this question, we established an in vivo assay in which 
substrate stability can be compared in the presence and absence of Acm1 (Figure 2.1). 
We used yeast cells harboring plasmids that conditionally express protein A-tagged 
substrates from the galactose-inducible GAL1 promoter and a stabilized Acm1 mutant 
(Acm1Δ52), which retains its central Cdh1 inhibitory domain [119], from the 
methionine-repressible MET25 promoter. The stable Acm1Δ52 mutant was necessary 
because Acm1 itself is highly unstable in G1 due to an APC-independent proteolytic 
mechanism [119]. Cells were first arrested in G1, when APC/CCdh1 is active, using α-
factor pheromone. Substrate expression was then induced briefly with galactose either 
in the absence or presence of methionine to control Acm1Δ52 expression. Finally, 
substrate expression was terminated with glucose and cycloheximide and stability 
monitored over time by anti-protein A immunoblotting.  
        We tested a panel of 15 known Cdh1 substrates (Table 3.1), including proteins 
containing functional KEN- and D-box consensus motifs, either a KEN- or D-box but not 
both, a non-canonical degron motif without consensus KEN- or D-boxes, or otherwise 
undefined degrons. The presence of Acm1 strongly stabilized all Cdh1 substrates, 
regardless of degron type (Figure 3.1, Figure 3.2, and Table 3.1).  
        This result could be explained either by Acm1 having a general effect on APC/C 
catalytic function independent of competing for substrate binding, or by all substrates 
having one or more common or overlapping docking sites required for ubiquitylation by 
APC/C. Currently, there is no evidence that Acm1 directly inhibits APC/C’s catalytic 
activity towards substrates. Instead, current models for Acm1 action suggest it acts as a 



































Figure 3.1 Acm1 blocks in vivo proteolysis of diverse Cdh1 substrates that contain 
canonical D-box and/or KEN-box degrons.  
Stability of the representative Cdh1 substrates that contain canonical D-box and/or KEN-
box degrons, expressed with C-terminal protein A epitope tags, was monitored over 
time by anti-protein A immunoblot in the absence or presence of the Acm1Δ52-protein 
A fusion protein (labeled as Acm1 in all panels). Time 0 is the point where protein 
expression is terminated. Both substrate and Acm1 were detected with anti-protein A 
antibody. G6PD is a load control in all panels. When present, “*” indicates that two 
different exposures of the same blot are compared, separated by a white bar, so that 
the time 0 signals are of comparable intensity. This sometimes provides a better 
visualization of differences in substrate half-lives between the two conditions because 
stabilization can lead to increased steady-state protein levels. See Table 3.1 for results 











Figure 3.2 Acm1 blocks in vivo proteolysis of diverse Cdh1 substrates that lack canonical 
D-box and KEN-box degrons. 
Same as Figure 3.1 with the representative Cdh1 substrates that lack canonical D-box 
and/or KEN-box degrons. See Table 3.1 for results from complete substrate set. Three 




















Table 3.1 Summary of APC/CCdh1 substrates and results 
 













Ase1 [130]    RQLFd   X X X NTe 
Cdc5 [103, 
131, 132] 
X X   X X X  
Cdc20 [103, 
132, 133]  
X    X X   
Cik1 [101]    undefinedf X X  X 
Cin8 [104]  X  MPLR X X X  
Clb2 [28, 
134]  
X X   X X X NT 
Fin1 [135]  X    X X   
Iqg1 [100]    undefinedg X X  NT 
Kip1 [102]    undefinedh X X X NT 
Mps1 [136]  X    X X   
Nrm1 [137]  X    X X   
Pds1 [88, 
138, 139]  
X X   X X X  
Sgo1 [96]     NKSEN X X X NT 
Spo12 [140]     undefinedi X X X NT 
Spo13 [93]     LxExxxN X X X NT 
 
a Sources providing evidence for functional degrons or degron-containing regions are 
included after each substrate name. Underlining indicates substrates that lack a 
consensus D-box motif required for their APC/C-mediated proteolysis. 
b Only degrons with experimental evidence demonstrating their requirement for 
substrate degradation are noted with X. 
c Stabilization (denoted with X) is defined as a minimum of 30-min increase in the time 
required to reach 50% of the initial protein level compared with control. The Acm1 
column reports results of assays measuring inhibition of protein degradation by the 







dependence of substrate degradation on the D-box, KEN-box, and ABBA motif receptor 
sites of the Cdh1 WD40 domain. 
d RQLF sequence in Ase1 was reported as a D-box but does not match the RXXL D-box 
consensus motif. 
e NT, not tested. 
f The N-terminal 80 amino acids of Cik1 are necessary and sufficient for degradation but 
lack consensus degron motifs. 
g The N-terminal 42 amino acids of Iqg1 are required for degradation but lack consensus 
degron motifs. 
h The C-terminal 101 amino acids of Kip1 are necessary and sufficient for degradation 
but lack consensus degron motifs. 























3.2.2 The ABBA motif in Acm1 is a functional APC/CCdh1 degron 
 
        To independently test if diverse Cdh1 substrates share a common docking site we 
engineered yeast strains expressing cdh1 mutant alleles with altered degron binding 
sites to compare the stability of the same substrate collection with a wild-type CDH1 
strain. Docking sites for the KEN-box, D-box, and ABBA motif have been identified 
through high resolution structural studies [24, 25, 60, 88, 98], although the ABBA motif 
has not been demonstrated to be a functional in vivo degron for APC/CCdh1 as it is for 
APC/CCdc20 [97, 99]. It was first identified as an element in Acm1 required for high 
affinity binding and inhibition of budding yeast APC/CCdh1 [108, 109]. Replacement of 
amino acids in all three of these Cdh1 docking sites disrupts binding of their respective 
ligand motifs in vitro [60, 88, 141]. For strain validation we monitored endogenous Clb2 
levels in cycling and G1-arrested cells. Clb2 remained stable in G1 in the cdh1dbr and 
cdh1kbr strains containing mutations in the D-box receptor and KEN-box receptor, 
respectively, but was degraded in the cdh1amr strain containing mutations in the ABBA 
motif receptor (Figure 3.3A), consistent with the presence of functional D- and KEN-
boxes in Clb2 that direct its APC/C-mediated degradation [28, 134]. Stabilization of 
endogenous Clb2 was not due to differences in expression level of the mutant proteins 
(Figure 3.3B) or efficiency of G1 arrest (Figure 3.3C). The receptor mutations also did not 
disrupt overall Cdh1 structure because the Cdh1dbr and Cdh1kbr proteins still interacted 
by co-IP with Acm1 via its other interaction motifs (Figure 3.4A). All three receptor 
mutants also interacted with the core APC/C similar to wild-type Cdh1 (Figure 3.4B).   
        We tested if the Acm1 ABBA motif is a functional APC/CCdh1 degron using the same 
assay from Figure 3.1 and Figure 3.2, except with Acm1Δ52 expressed from the GAL1 
promoter as the substrate. Paradoxically, Acm1 can be converted into an APC/CCdh1 
substrate in vitro by mutation of its central KEN- and D-box motifs [108, 109, 115]. 
Consistent with these in vitro results, mutation of the D- and KEN-box motifs in 
Acm1Δ52 (Acm1db/kb) destabilized the protein in vivo, dependent on Cdh1 (Figure 3.5A). 







stabilized the protein (Figure 3.5B). In the cdh1amr strain Acm1Δ52db/kb was strongly 
stabilized compared to a wild-type CDH1 strain and was more stable than in the cdh1dbr 
and cdh1kbr strains (Figure 3.5C). Taken together, these results demonstrate that the 
ABBA motif in Acm1 is a functional APC/CCdh1 degron. With this information in hand, we 




















Figure 3.3 The strains expressing cdh1 mutant alleles with altered degron binding are 
constructed successfully. 
A. Immunoblot analysis of endogenous Clb2 levels in asynchronous and α-factor-treated 
G1 cultures of the indicated strains. WT is the parental strain from which cdh1Δ was 
engineered. The remaining strains have 3FLAG-CDH1 or degron receptor mutant alleles 
(dbr, D-box receptor mutations; kbr, KEN-box receptor mutations; amr, ABBA motif 
receptor mutations) expressed from the CDH1 promoter integrated into cdh1Δ. B. Anti-
FLAG immunoblot from whole cell extracts of asynchronous cultures of cdh1Δ and the 
indicated derivative strains demonstrating equivalent expression from the integrated 
3FLAG-cdh1 alleles. C. The ability of the integrated 3FLAG-CDH1, 3FLAG-cdh1dbr, and 
3FLAG-cdh1kbr strains used for substrate stability assays to stably arrest in G1 in 
response to α-factor treatment was determined by anti-Acm1 immunoblot and flow 







was terminated at time 0. Flow cytometry data are from 60-min point to illustrate 





























Figure 3.4 Overall Cdh1 structure is not disrupted by mutations of D-, KEN-box and ABBA 
motif receptors. 
A. The interaction of endogenous Acm1 with 3FLAG-Cdh1dbr and 3FLAG-Cdh1kbr mutants 
was assessed by anti-FLAG co-IP. WCE, whole cell extracts. B. The interaction of 3FLAG-
Cdh1 and the three degron docking site mutants with the core APC was assessed by 















Figure 3.5 The ABBA motif is a functional APC/CCdh1 degron in budding yeast. 
A. Stability of Acm1Δ52-protein A and a variant with mutations in the central D- and 
KEN-boxes (Acm1db/kb) was evaluated in CDH1 and cdh1Δ strain backgrounds. B. Same as 
panel F comparing stability of Acm1db/kb with a variant containing an additional mutation 
of the ABBA motif (Acm1db/kb/am) in the CDH1 strain. C. Stability of Acm1Δ52-protein A 
with mutations in its D- and KEN-boxes was compared in strains expressing either wild-
type CDH1 or one of three cdh1 degron receptor mutants. In this experiment Acm1 was 
















3.2.3 The D-box receptor on Cdh1 is required for efficient proteolysis of most, if not all, 
Cdh1 substrates 
 
        Strikingly, mutation of the D-box receptor site on Cdh1 by alteration of just 4 
conserved amino acids [108, 141] strongly stabilized all 15 Cdh1 substrates in our in vivo 
stability assay (Figure 3.6, Figure 3.7, and Table 3.1), although not always to the same 
degree as Acm1Δ52 overexpression. This result was surprising in that roughly half of the 
substrates tested lack recognizable, consensus D-box motifs. The variability in the 
stabilizing effect across substrates could reflect different contributions of other 
elements to Cdh1 binding or differences in the nature of interactions with the D-box 











Figure 3.6 The D-box receptor on Cdh1 is essential for normal proteolysis of all 
substrates containing consensus D-box degrons. 
A. Stability assays (based on the protocol from Figure 2.1) with representative protein A-
tagged substrates containing consensus D-box degrons were performed in G1-arrested 
CDH1 and cdh1dbr strains. Substrate expression from GAL1p was terminated at time 0 
and protein level monitored over time by anti-protein A immunoblotting. G6PD is a load 
control. An “*” indicates that two different exposures of the same blot are compared 
with comparable time 0 intensities. See Table 3.1 for results from complete substrate 
set. All experiments in panels A were performed three times with equivalent results. B. 
Example flow cytometry results from cells at the 60-min point in the assays (Pds1 








Figure 3.7 The D-box receptor on Cdh1 is essential for normal proteolysis of all 
substrates that lack functional D-box consensus motifs. 
Same as Figure 3.6 panel A with substrates that lack functional D-box consensus motifs. 
See Table 3.1 for results from complete substrate set. Three independent experiments 








3.2.4 KEN-box and ABBA motif receptors are required for normal proteolysis of distinct 
subsets of Cdh1 substrates 
 
        We next explored the requirement for functional KEN-box and ABBA motif receptor 
sites on Cdh1 for substrate proteolysis. Unlike the universal dependence of normal 
proteolysis rates on the D-box receptor, the proteolysis of some substrates appeared 
completely independent of the KEN-box receptor in the cdh1kbr strain (Figure 3.8 and 
Table 3.1). Nonetheless, proteolysis of a subset of substrates was strongly impaired in 
cdh1kbr cells (Figure 3.9, Figure 3.10, and Table 3.1). For the most part, substrates 
exhibiting dependence on the KEN-box receptor contained consensus KEN-box motifs. In 
some cases, like Spo12, KEN sequences have not been functionally linked to APC/C-
mediated proteolysis. The Spo13 and Sgo1 proteins were interesting in that proteolysis 
was strongly dependent on the KEN-box receptor yet neither contains a consensus KEN-
box motif. This suggests that variations on this motif can also functionally engage the 
KEN-box docking site on Cdh1, consistent with experiments using the GxEN motif in XKid 
[88]. The Kip1 protein also lacks a KEN-box in the C-terminal region required for APC/C-
mediated proteolysis [102] but requires the KEN-box receptor for efficient proteolysis in 
our assay.   
        We tested a subset of our Cdh1 substrate panel in the cdh1amr strain, including 
those that showed no dependence on the KEN-box receptor, and found that the stability 
of most was unaffected by disruption of the ABBA motif binding site (Figure 3.11 and 
Table 3.1). Several substrates exhibited a very slight increase in stability that could 
reflect a minor overall effect of ABBA motif receptor mutations on Cdh1 function or a 
weak contribution to substrate binding, but did not meet our criteria for stabilization. 
We found a single Cdh1 substrate, Cik1, whose stability was strongly dependent on the 
ABBA motif receptor site (Figure 3.12), even though the Cik1 N-terminus that is 
necessary and sufficient for APC/C-mediated proteolysis [101] lacks any sequence 







promoting binding of the inhibitor Acm1 to Cdh1, the ABBA motif (or variants of it) 



























Figure 3.8 The KEN-box receptor on Cdh1 is not required for normal proteolysis of a 
subset of substrates. 
Same as Figure 3.6 panel A using a strain expressing the cdh1kbr allele with altered KEN-
box receptor. Substrates with stability independent of KEN-box receptor. See Table 3.1 
for results from complete substrate set. Three independent experiments were 












Figure 3.9 The KEN-box receptor on Cdh1 is required for normal proteolysis of a subset 
of substrates containing consensus KEN-box degron. 
Same as Figure 3.8. Substrates containing consensus KEN-box degron with stability 
dependent on KEN-box receptor. The white bars in the Cin8 and Clb2 blots indicate that 
lanes corresponding to the cdh1dbr experiment were cropped from the middle. See Table 
3.1 for results from complete substrate set. Three independent experiments were 









Figure 3.10 The KEN-box receptor on Cdh1 is required for normal proteolysis of a subset 
of substrates lacking functional KEN-box consensus motif. 
A. Same as Figure 3.8. Substrates lacking functional KEN-box consensus motif with 
stability dependent on KEN-box receptor. See Table 3.1 for results from complete 
substrate set. Three independent experiments were performed for all substrates with 
equivalent results. B. Example flow cytometry results from cells at time = 60 min (Cdc5 









Figure 3.11 The ABBA motif receptor on Cdh1 is not required for normal proteolysis of a 
subset of substrates. 
Same as Figure 3.6 panel A using a strain expressing the cdh1amr allele with altered ABBA 
motif receptor. Substrates with stability independent of ABBA motif receptor. See Table 
3.1 for results from complete substrate set. Three independent experiments were 











Figure 3.12 The ABBA motif receptor on Cdh1 is required for normal proteolysis of Cik1. 
Same as Figure 3.11. Cik1 was the lone substrate tested that exhibited strong ABBA 





















3.2.5 Novel APC/C substrates can be identified using in vivo stability assays and Cdh1 
inhibition by Acm1 
 
        The universal stabilizing effect of Acm1Δ52 on Cdh1 substrates in our assay in 
Figure 3.1 and Figure 3.2 suggested that it could be used as a tool for identifying novel 
substrates. To explore this idea we tested two proteins, Ipl1 and Swe1, whose 
abundances during the cell cycle were previously demonstrated to be dependent on 
APC/C function [31] but, to our knowledge, have not been validated as direct APC/C 
substrates. Ipl1 is the budding yeast ortholog of Aurora B kinase and Swe1 is the 
ortholog of Wee1 kinase. The stability of both proteins in G1-arrested cells increased 
when Acm1Δ52 was co-expressed (Figure 3.13A). To verify that APC/C can target Ipl1 
and Swe1 for degradation we compared their stability in CDH1 and cdh1dbr strains. 
Stability of both Ipl1 and Swe1 increased in the cdh1dbr strain, confirming their 
APC/CCdh1-mediated turnover and demonstrating its D-box receptor dependence (Figure 
3.13B). While it remains unclear if APC/C-mediated degradation of Ipl1 and Swe1 has 
functional significance in yeast, this work demonstrates that, in principle, our in vivo 
assay can be used as a tool to determine if a protein of interest is recognized as a 
substrate by APC/CCdh1 in a physiological environment. Given the apparent conservation 
of APC/C structure and substrate recognition [24], it could potentially be used to test 









Figure 3.13 Novel APC/C substrates can be identified using the in vivo Cdh1 inhibition 
assay. 
A. Same as Figure 3.1 with candidate Cdh1 substrates Ipl1 and Swe1. B. Same as Figure 





















        The most significant conclusion from this study is that efficient degradation of most, 
if not all, APC/CCdh1 substrates requires engagement of the D-box receptor site on Cdh1, 
despite the lack of a universal D-box sequence motif common to all substrates. Thus, the 
apparent diversity in APC/CCdh1 substrate degron motifs may not reflect complexity in 
the mechanisms of substrate recognition. The D-box was the first APC/C degron 
identified and characterized [86] and it contains elements that bind both to the WD40 
domain of the coactivator proteins as well as the Apc10 subunit of the core APC/C [25, 
141-147]. The broad requirement of the D-box receptor for efficient APC/CCdh1 substrate 
proteolysis suggests that the D-box may contribute more than just binding affinity, 
consistent with recent structural and mechanistic studies. D-box engagement may be 
important for positioning substrate lysines for ubiquitin transfer, for the coactivator-
induced conformational change in the core APC/C that brings the catalytic RING module 
into close proximity with the substrate [24], for enhancing functional interaction with 
the E2 [148], or enhancing catalysis in some other way. Despite the universal 
dependence of Cdh1 substrate degradation on an intact D-box receptor, we note that 
turnover of the artificial Acm1db/kb mutant was only slightly impaired in the cdh1dbr strain 
(Figure 3.5C), presumably due to the unusual contributions of other high affinity docking 
motifs required for effective Cdh1 inhibition [88, 108, 109].  
        In contrast to the D-box, the selective requirement of other motifs, e.g. the KEN-box 
and ABBA motif, for substrate proteolysis is consistent with these motifs providing 
primarily specificity and binding affinity and not a crucial contribution to the catalytic 
reaction. While it is unclear what the functional implications of having a KEN box versus 
an ABBA motif are, the use of a variety of short linear motifs for substrate docking 
ensures highly selective binding while allowing for flexibility in the substrate structural 
requirements. It seems likely that additional docking sites on Cdh1 remain undiscovered. 
For example, it is unclear how a D-box alone could provide sufficient binding affinity and 







several of the substrates examined here (e.g. Nrm1, Mps1, and Cdc20) was independent 
of both the KEN-box and ABBA motif receptors. Nonetheless, the widespread use of D-
box receptor docking argues that all Cdh1 substrates share some aspects of recognition 
and processing by APC/CCdh1.  
        The ABBA motif was originally identified in Acm1 as a unique element required for 
full APC/CCdh1 inhibition [108]. Our results with Cik1 and the Acm1db/kb mutant 
demonstrate clearly that the ABBA motif is another functional APC/CCdh1 degron, 
consistent with recent reports identifying the ABBA motif as a degron for APC/CCdc20 in 
both yeast and humans [97, 99] and with prior in vitro work with Acm1 [108]. 
Considering that Acm1 possesses three distinct consensus APC/CCdh1 degrons, it remains 
unclear how it evades ubiquitination by APC/CCdh1, although lack of suitably positioned 
lysines has been proposed [108]. The ABBA motif that binds budding yeast Cdc20, 
identified in the S phase cyclin Clb5 [99], is distinct from the Acm1 ABBA motif that 
binds Cdh1. The two differ primarily at the beginning of the motif, where Clb5 orthologs 
contain a pair of conserved basic amino acids instead of the conserved phenylalanine of 
the ABBA motif consensus sequence Fx(I/V/L)(F/Y/H)x(D/E) [99]. In principle, differences 
in the ABBA motif receptor of Cdh1 and Cdc20 could contribute to the distinct 
specificities of the two APC/C coactivators, although it does not seem to contribute 
significantly to recognition of most Cdh1 substrates. Interestingly, the ABBA motif 
recognized by human APC/CCdc20 more closely resembles the motif recognized by 
APC/CCdh1 in budding yeast, and the residues in human Cdc20 that form the ABBA motif 
receptor are likewise similar to those found in budding yeast Cdh1 [98].  
        Our results emphasize that the current definitions of the three best characterized 
APC/C substrate degrons (D-box, KEN-box, and ABBA motif) are still incomplete. We 
identified substrates that require the D-box, KEN-box and ABBA motif receptors yet lack 
sequences that match the current consensuses for these degrons. Additional work is 
needed to identify the functional degrons in many substrates lacking the consensus 
motifs, for example the D-box in the kinesin Cin8, the D- and KEN-boxes in the kinesin 







in Sgo1 that is required for its APC/C-mediated proteolysis was reported to be part of an 
unconventional D-box [96] yet resembles the KEN-box consensus as well. Mutations of 
consensus D- and KEN-box sequences in the small Spo12 protein were previously 
reported to have no effect on Spo12 turnover [140]. However, our results clearly 
demonstrate that Spo12 degradation by the APC/C is dependent on functional D- and 
KEN-box receptor sites, suggesting either that mutation of Spo12 degrons renders the 
protein unstable independent of the APC/C or that cryptic D- and KEN-boxes exist. 
Additional structural studies will be crucial in the future to characterize how consensus 
and non-consensus degron sequences can bind the same receptor sites to promote 
substrate ubiquitylation. And it still remains unclear which docking sites some of the 
alternative degrons reported for APC/C substrates bind to and which may contribute to 
degradation in other ways aside from binding the coactivator, for example by promoting 
nuclear localization [103]. Given the prevalence of unconventional degron motifs in 
Cdh1 substrates from other species and the high conservation of APC/C core and 
coactivator subunits, our findings likely have general relevance to APC/C substrate 
recognition in all eukaryotes. 
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CHAPTER 4. A NOVEL EXTENSION OF THE DESTRUCTION BOX IS A CRITICAL 




        APC activity is tightly regulated by multiple mechanisms, for example 
pseudosubstrate inhibitors, which bind tightly to the degron receptor sites on the APC 
co-activators, Cdc20 and Cdh1, to competitively block substrate binding. 
Pseudosubstrate inhibitors have been identified throughout the eukaryotes, including in 
yeast, plant, and metazoan species [58-67]. Although diverse mechanisms are utilized by 
different pseudosubstrate inhibitors, APC degrons are universally required for their 
inhibitory function. In fission yeast, APCCdc20 inhibition by MCC requires Mad3 to bind 
Cdc20 using a KEN-box, which not only prevents Cdc20 from binding KEN-boxes on 
substrates, but also displaces Cdc20 toward Apc5 to disrupt the formation of the D-box 
receptor composed of both Cdc20 and Apc10 [60], effectively preventing substrate 
ubiquitination. In human MCC, a D-box and a second KEN-box on BUBR1 are required to 
bind a second Cdc20 molecule to inhibit APCCdc20 [111]. Although Emi1 inhibits APC 
function by blocking binding of UbcH10 and Ube2S to the APC, the D-box is also used to 
bind the D-box co-receptor of Cdh1 and Apc10 to compete with real substrates for APC 
binding [112-114]. Mes1 inhibits APC function by utilizing a mechanism clearly different 
from MCC and Emi1, which is also strongly dependent on the APC degrons. Different 
from MCC and Emi1, Mes1 is a true substrate as well as a potent inhibitor of APC, and 
both its APC-mediated degradation and APC inhibition function are dependent on both 
D-box and KEN-box [61]. Mes1 is a poor substrate but a good inhibitor of the meiosis-







fission yeast Cdc20 and must be degraded via Cdc20 in meiosis I to allow APCMfr1 
activation for meiosis II [149]. It is still not clear how the very small Mes1 protein can 
selectively inhibit Mfr1 using the same degron motifs that are recognized efficiently as 
substrates by Cdc20.  
        Like Mes1, it is still unclear what distinguishes other pseudosubstrate inhibitors 
from true substrates, and how they evade ubiquitination and degradation. In budding 
yeast, Cdh1 is regulated by a pseudosubstrate inhibitor called Acm1, which uses both D-
box, KEN-box, and ABBA motifs to stably bind and inhibit APCCdh1 [59, 107-109]. 
However, little is known about what makes Acm1 an inhibitor rather than a true APCCdh1 
substrate. Answering this question will help us better understand the requirements for 
APC substrate recognition and specificity. Since APC is considered an attractive cancer 
chemotherapeutic target, the knowledge of the inhibition mechanism of Acm1, a 
natural APC inhibitor, can guide development of selective APC inhibitors in the future. 
        Several different models of APCCdh1 inhibition by Acm1 were proposed previously. 
One model suggested that Acm1 evades degradation by APCCdh1 by utilizing the 
additional Cdh1 binding sites which confer extremely tight binding to APCCdh1, as well as 
the inaccessibility of ubiquitinatable lysines [108]. Another model attributes the 
inhibitory function of Acm1 to its unique D- and KEN-box sequences, which was 
supported by the observation that Acm1 can be converted into an efficient APCCdh1 
substrate in vitro by the mutation of its D-box and KEN-box degrons [115]. To test if high 
binding affinity is required to prevent Acm1 degradation via APCCdh1 I tested the effect 
of making different degron mutation combinations on Acm1 stability in G1-arrested cells, 
when APCCdh1 is active. I used the same Acm1Δ52-Protein A fusion protein used in 
Chapter 3 as the substrate. I focused on the central inhibitory domain of Acm1 which is 
a compact region containing several APC degrons (Figure 1.7). By comparing the 
stabilities of different mutant Acm1 proteins, I was able to determine how important 
each degron is in preventing Acm1 from being degraded by APCCdh1. The results revealed 
that mutation of the D-box was necessary and sufficient to convert Acm1 into an 







terminus that is responsible for distinguishing Acm1 from substrates. Moreover, this 
region is critically important for degradation of APCCdh1 substrates but does not 
contribute to substrate binding. These results are consistent with my data that the D-
box receptor on Cdh1 is generally required for proteolysis of APCCdh1 substrates (Chapter 
3) and suggests that the D-box has an additional, unanticipated function in activating 
APCCdh1 enzymatic capacity. 
       
4.2 Results 
 
4.2.1 The central D-box plays a critical role in protecting Acm1 from APCCdh1-mediated 
degradation in vivo 
 
        Since both in vitro [115] and in vivo (Figure 3.5) data suggest that Acm1 can be 
converted into an APCCdh1 substrate by mutating its D- and KEN-box degrons, I proposed 
that Acm1 is inherently no different than substrates, but binds co-activators with an 
unusually high affinity that interferes with the poly-ubiquitination process. If this 
hypothesis is true, then deletion of any degrons should be able to decrease the affinity 
and thus convert Acm1 into a substrate. To test this hypothesis, I used the system 
established in Chapter 3 to study the APCCdh1-dependent stability of Acm1 in vivo.  Here I 
used Acm1Δ52 (as described in Chapter 3) which is stable in G1 phase to exclude APC-
independent degradation of Acm1. Acm1Δ52 variants with mutations of each individual 
degron motif were expressed to compare their stability in G1-arrested cells. 
Interestingly, only the D-box mutant Acm1 (Acm1db) showed a significant decrease in 
stability (Figure 4.1A). This result suggests that an intact D-box is important for Acm1 to 
avoid degradation mediated by APCCdh1, a paradoxical result considering the well-
defined role of D-boxes in targeting proteins to the APC for degradation. To further test 
the affinity-based hypothesis I combined mutations in other degrons with the D-box 







showed that additional mutations in other degrons do not further destabilize the 
Acm1db. In fact, additional mutation of the ABBA motif even resulted in strong 
stabilization (Figure 4.1B, C). Thus, the other degrons appear to play somewhat normal 
roles in promoting binding of Acm1 to Cdh1 and promoting ubiquitination. These results 
are inconsistent with the affinity model proposed above and suggest that the D-box 
instead possesses some unique property that suppresses APCCdh1 activity towards Acm1. 




















Figure 4.1 The D-box plays a critical role in protecting Acm1 from degradation by APCCdh1. 
A. Stability of both wild-type Acm1Δ52 and Acm1Δ52 variants with mutations of each 
individual degron motif expressed with C-terminal protein A epitope tags, was 
monitored over time by anti-protein A immunoblot. Time 0 is the point where protein 
expression is terminated. Acm1Δ52 was detected with anti-protein A antibody. G6PD is 
a load control in all panels. B. Same as panel A. with Acm1Δ52 variants with mutations 
of D-box combined with other each individual degron motif. One trial was performed. C. 
Quantification of the data in panel B. Three trials were performed. One-phase 
exponential decay nonlinear regression was used to plot the data to determine protein 











4.2.2 Acm1 can be converted into an efficient APCCdh1 substrate by altering a 
conserved sequence downstream from the D-box 
 
        To identify the unique D-box properties that protect Acm1 from being degraded by 
APCCdh1, I re-examined the sequence around the core D-box in Acm1. Alignment of ~50 
Acm1 fungal orthologs revealed a short, conserved region immediately downstream 
from the 9-residue D-box core (Figure 4.2A). This region in Acm1 (DEFKGYI) differs 
significantly from the corresponding sequence in Hsl1 (SFNKMNK), a well-defined 
APCCdh1 substrate which can bind APCCdh1 tightly. Therefore, I replaced this region in 
Acm1Δ52 with the corresponding sequence from Hsl1 and tested whether Acm1Δ52 
was converted into an APCCdh1 substrate. The mutant Acm1Δ52 (Acm1dbe) was degraded 
rapidly in G1-arrested cells in an APCCdh1-dependent manner (Figure 4.2B, C). This result 
demonstrated that this region is required to prevent Acm1 from being degraded by 
APCCdh1. To further define the key residues in this region, the first and last three residues 
were mutated individually (also replaced with the corresponding sequence from Hsl1), 
and the effects on Acm1Δ52 stability were compared in G1-arrested cells. Mutation of 
the first three residues (Acm1DEF) was sufficient to completely destabilize Acm1Δ52 
(Figure 4.3A), suggesting that these positions contribute more to the stabilizing property 
of the Acm1 D-box extension (DBE). The mutation of last three residues (Acm1GYI) also 
affect stability, but to a lesser extent (Figure 4.3A). Next, each of the first three residues 
in the DBE were mutated individually. Mutation of just the phenylalanine residue 
(Acm1F) destabilized Acm1Δ52 noticeably, suggesting an important contribution of this 
position to the stabilizing property of the Acm1 DBE (Figure 4.3B, C).  
        Since Acm1Δ52 with mutant DBE became an efficient APC substrate, it might be 
expected to compromise APCCdh1 inhibition. Indeed, in vivo data showed that the 
APCCdh1-degradable Acm1Δ52 (including both Acm1db and Acm1dbe) cannot suppress 
Cdh1-induced growth defect as well as wild-type Acm1Δ52 (Figure 4.4A), suggesting that 
suppression of Acm1 degradation by the unique D-box is important for its ability to 







function of Acm1, I compared the effect of wild-type Acm1, Acm1db, and Acm1 with the 
first three residues in DBE replaced with either the corresponding sequence from Hsl1 
(Acm1DEF-SFN) or just alanine (Acm1DEF-AAA) on the inhibition of APCCdh1 substrate 
degradation. Both Pds1, an APCCdh1 substrate, and either Acm1, Acm1db, Acm1DEF-SFN, or 
Acm1DEF-AAA were expressed, and the degradation of Pds1 was monitored in G1-arrested 
cells. Not surprisingly, the DBE mutation (replaced with either the corresponding 
sequence from Hsl1 or just alanine) significantly compromised the inhibitory function of 
Acm1Δ52, which is similar as the effect of D-box mutation (Figure 4.4B, C). These data 
together indicated that the DBE plays a critical role in APCCdh1 inhibition by protecting 




















Figure 4.2 The DBE blocks APCCdh1-dependent degradation of Acm1∆52. 
A. Conserved domains showed as a result of the alignment of ~50 Acm1 fungal 
orthologs. Alignment created with Clustal Omega and visualized in JalView. Each bar 
represents a single residue in the central inhibitory region of Acm1 and the bar height 
represents the extent of conservation (tall, yellow bars are invariant residues). The 
“KEN-like” represents the NEN labeled in Figure 1.8 and Figure 4.1A. B. Same as Figure 
4.1 panel A with wild-type Acm1Δ52 or Acm1Δ52 variants with mutations of either D-
box (Acm1db) or DBE (Acm1dbe). Three trials were performed with equivalent results. C. 











Figure 4.3 The first three residues (DEF), especially the phenylalanine residue, of the 
DBE play the most important role in blocking APCCdh1-dependent degradation of 
Acm1∆52. 
A. Same as Figure 4.2 panel B with Acm1Δ52 variants with mutations of the first three 
(acm1DEF), last three (acm1GYI), or all 6 residues (acm1dbe) of the DBE. One trial was 
performed. B. Same as panel A with Acm1Δ52 variants with mutations of the D, E, F, or 
the first three residues together of the DBE. One trial was performed. C. Quantification 
of the data in panel B. One-phase exponential decay nonlinear regression was used to 










Figure 4.4 The DBE plays a critical role in APCCdh1 inhibition by Acm1. 
A. 5-fold serial dilutions of strain YKA233 expressing the indicated proteins from the 
GAL1 promoter were spotted on YP media plates containing either glucose or galactose 
and grown for several days at 30 °C. B. Same as Figure 4.2 panel B with both Pds1 and 
either wild-type Acm1Δ52 or Acm1Δ52 with mutant D-box or DBE were expressed 
together.  When present, “*” indicates that two different exposures of the same blot are 
compared, separated by a white bar, so that the time 0 signals are of comparable 
intensity. This sometimes provides a better visualization of differences in substrate half-
lives between the two conditions because stabilization can lead to increased steady-
state protein levels. One trial was performed. C. Quantification of the data in panel B. 
One-phase exponential decay nonlinear regression was used to plot the data to 









4.2.3 APCCdh1 substrates can be stabilized by replacing the DBE with the corresponding 
sequence from Acm1 
 
        Since the DBE in Acm1 is necessary for the inhibitory function of Acm1 (Figure 4.2, 
4.3, 4.4), I next examined whether this region is sufficient to block degradation of 
otherwise good APCCdh1 substrates. If so, it would suggest that the DBE plays a critical 
role in distinguishing pseudosubstrates from true substrates. The DBEs of four APCCdh1 
substrates containing well-defined D-boxes were mutated into the corresponding DBE 
sequence from Acm1. The stability of these mutant APCCdh1 substrates were measured 
in G1-arrested cells. All four APCCdh1 substrates were stabilized in the presence of the 
Acm1 DBE sequence (Figure 4.5). Pds1, and Fin1 were almost completely stabilized by 
the DBE swap, while Cdc20 was still degraded with a much slower rate than the wild-
type, consistent with its additional APCCdh1-independent degradation mechanism [133]. 
Hsl1 exhibits a more complicated result. The full-length C-terminus of Hsl1 was not 
stabilized by the DBE swap (data not shown), while a cryptic fragment was (Figure 4.5). 
Careful examination on the full-length C-terminus of Hsl1 reveals several motifs with 
consensus APC degron sequences including two RxxLs and two KENs. Therefore, the 
mutation of only one DBE may be not enough to abolish APC-mediated degradation of 
this fragment, while the cryptic small fragment which can be stabilized by the single DBE 
mutation may only has one D-box. These results together demonstrate that the DBE in 
Acm1 is sufficient to block degradation of otherwise efficient APCCdh1 substrates and 
suggests that this element can play a decisive role in distinguishing a pseudosubstrate 
inhibitor from a true substrate. However, it is still unknown whether the stabilization of 
these mutant APCCdh1 substrates is due to abolished D-box recognition by APCCdh1, or the 









Figure 4.5 APCCdh1 substrates are stabilized by mutating the DBE to the corresponding 
sequence from Acm1 
Same as Figure 4.2 panel B with both wild-type and DBE mutant APCCdh1 substrates 
tested. When present, “*” indicates that two different exposures of the same blot are 
compared, separated by a white bar, so that the time 0 signals are of comparable 
intensity. This sometimes provides a better visualization of differences in substrate half-
lives between the two conditions because stabilization can lead to increased steady-












4.2.4 APCCdh1 substrates can be converted into weak APCCdh1 pseudosubstrate 
inhibitors by replacing the DBE with the corresponding sequence from Acm1 
 
        To begin determining the mechanism of stabilization of the APCCdh1 substrates with 
mutant DBE, I detected whether these mutants can serve as pseudosubstrate inhibitors 
like Acm1 in G1 phase. If stabilization is due to abolishment of D-box recognition by 
APCCdh1, the mutant APCCdh1 substrates should not be able to bind and inhibit APCCdh1 
activity. Conversely, if they can function as inhibitors, it suggests the mutations of the 
DBE confers some unique property on these D-boxes, which allows them to still 
associate with APCCdh1 but evade degradation, and further implicates the D-box in 
activating APC’s enzymatic capacity. The stabilities of APCCdh1 substrates were compared 
in the presence and absence of an additional substrate of wild-type or DBE mutant 
sequence. Interestingly, both Fin1dbe (Figure 4.6A) and Pds1dbe (Figure 4.6B) acquire 
weak inhibitory function compared with their wild-type forms, demonstrating that the 
DEB mutations do not prevent binding to APCCdh1. However, the inhibitory function of 
these mutant APCCdh1 substrates is not as strong as Acm1, most likely due to the much 
higher collective affinity of the Acm1 degrons for Cdh1, which more effectively 
competes with substrates for binding.   
        Next I directly tested if the DBE influences substrate binding to Cdh1 by performing 
co-immunoprecipitation (co-IP). The mutation of DBE did not impair the association of 
Fin1 with Cdh1 by co-IP (Figure 4.7), consistent with the inhibition results (Figure 4.6). 
These results together demonstrate that DBE performs some function distinct from the 









Figure 4.6 APCCdh1 substrates can be converted into weak APCCdh1 pseudosubstrate 
inhibitors by replacing the DBE with the corresponding one from Acm1 
A. Same as Figure 4.4 panel B with both wild-type Pds1 and either wild-type or DBE 
mutant Fin1 expressed together. One trial was performed. B. Same as panel A with both 












Figure 4.7 The DBE region does not influence substrate binding to Cdh1 
The interaction of the c-terminus of 3Flag-Cdh1 (Flag-Cdh1CT) with wild-type and DBE 
mutant Fin1 was assessed by anti-FLAG co-IP in acm1∆ cells. Both wild-type and mutant 
Fin1 are labelled by 3HA tag and detected by Western blot using anti-HA antibody. WCL, 
whole cell lysates. fin1dbe, fin1 with DBE mutated to the corresponding one from Acm1. 
fin1dbeA, fin1 with all residues of DBE mutated to alanine. Two independent experiments 




















4.2.5 The DBE region is generally important for substrate processing by APCCdh1   
 
        The results so far reveal a role for the DBE in distinguishing pseudosubstrate 
inhibitors from true substrates. The importance of the DBE region in substrates has not 
previously been studied. Sequence alignment of the DBEs in different APCCdh1 substrates 
containing well-defined D-boxes did not show any similarity (Figure 4.8), which raises a 
question: is the DBE generally important for substrate processing by APCCdh1? To answer 
this question, DBE residues in the Cdh1 substrate Fin1 were mutated to alanine residues 
and the mutant protein stability was measured in G1-arrested cells. Interestingly, 
although no sequence conservation exists across APCCdh1 substrates in this region, Fin1 
was completely stabilized by mutating residues in the DBE to alanines (Figure 4.9A). This 
demonstrates that the DBE region plays a critically important role in promoting 
substrate degradation. I also tested the effect of alanine substitutions in the Acm1 DBE 
and found that they destabilized Acm1Δ52 similar to mutation of the D-box RxxL core 
sequence, but less so than mutating the DBE to the sequence from a substrate like Hsl1 
(Figure 4.9B). Together, these results indicate a complex role for this region in 
controlling the fate of a bound protein. Some sequence, like those in Acm1 actively 
inhibit APC. Other sequence, like those in Fin1 and Hsl1, promote ubiquitination and 
degradation. And other sequence, like poly-alanine, are simply non-functional.  
        In order to identify the most critical functional residues in the DBE, both mutant 
Fin1 and Acm1 were subjected to additional alanine mutagenesis as specific sites or 
subsets of sites within the DBE. Their relative stabilities were compared in G1-arrested 
cells. The first three residues of the DBEs are functionally important in both Fin1 and 
Acm1 (Figure 4.10A, B). This is consistent with the observation that the replacement of 
the first three residues of the DBE in Acm1 with the corresponding sequence in Hsl1 can 
significantly destabilize Acm1Δ52 (Figure 4.4A). The results together indicate the 
decisive role these three residues play in APCCdh1 interaction with both true substrates 










Figure 4.8 Alignment of the DBE sequences from different APCCdh1 substrates as well as 
Acm1 reveals no similarity among them. 










Figure 4.9 The DBEs in both Fin1 and Acm1 are important for substrate processing by 
APCCdh1 
Same as Figure 4.5 with both wild-type and DBE mutant Fin1 and Acm1 tested. When 
present, “*” indicates that two different exposures of the same blot are compared, 
separated by a white bar, so that the time 0 signals are of comparable intensity. This 
sometimes provides a better visualization of differences in substrate half-lives between 













Figure 4.10 The first three residues of DBE in both Fin1 and Acm1 play critical roles in 
substrate processing by APCCdh1 
Same as Figure 4.9 with both wild-type and mutant Fin1 and Acm1 with mutations of 
the first three, last four, or all 7 residues of the DBE tested. When present, “*” indicates 
that two different exposures of the same blot are compared, separated by a white bar, 
so that the time 0 signals are of comparable intensity. This sometimes provides a better 
visualization of differences in substrate half-lives between the two conditions because 














        Although many APCCdh1 pseudosubstrate inhibitors have been identified in diverse 
model systems [58-67], for most of them, it is still unclear what distinguishes them from 
true substrates, and how they evade ubiquitination and degradation. One model from 
previous study attributes the unique property of Acm1 to its additional Cdh1 binding 
sites and the inaccessibility of ubiquitinatable lysines [108]. However, previous study in 
our lab indicates the unique D- and KEN-box sequences of Acm1 play critical roles in the 
inhibitory function of Acm1 [115]. A new component of the D-box, DBE, was identified 
in my study. The identification of DBE largely answers this question. My study supports 
the model proposed by our lab, and further explains how the D-box in Acm1 is unique 
and different from those on APCCdh1 substrates.  
        A question that remains to be answered is how DBE functions in substrate 
processing by APCCdh1. My study shows it is responsible for not only APCCdh1 inhibition by 
Acm1, but also ubiquitination and degradation of APCCdh1 substrates. Such critically 
important function of this motif promotes us to speculate it contributes to not only 
substrate docking, but also other important process such as substrate processing by 
APCCdh1, which may be the reason of the broad requirement of D-box receptor for 
substrate degradation. This hypothesis is supported by my study that the DBE does not 
contribute to APCCdh1 binding of the substrates, but their ubiquitination. Previous study 
in which an artificial fusion APCCdh1 substrate was used also suggest DBE together with 
core D-box may function in activating APCCdh1 enzymatic capacity [148]. The N-terminus 
of securin was linked to APC10 to allow this artificial substrate to bind APC tightly and 
be ubiquitinated at a low rate in the absence of Cdh1 [148]. Ubiquitination of this 
substrate was shown to be stimulated by Cdh1, due to the enhancement of E2 efficiency 
[148]. Moreover, the interaction between Cdh1 and degron is required for full E2 
stimulation [148]. Therefore, substrate degrons may contribute to APC activity 








substrate ubiquitination is still largely unknown, and more work detecting the 
interaction between DBE and APCCdh1 are required in future.  
        Another question that remains to be answered is what sequences, or higher 
structures, DBE should have to be functional, since DBEs from different APCCdh1 
substrates show no similarity in their sequences. Since Fin1 can be completely stabilized 
by the mutation of the DBE to alanine residues, functional conservation must exist on 
DBE in APCCdh1 substrates. Therefore, it is more likely that the conservation exists in 
higher structure rather than the linear sequence of DBE, which means the higher 



























CHAPTER 5. DISCUSSION AND FUTURE DIRECTION 
 
5.1 More degrons identification on APCCdh1 substrates 
 
        A fundamental and interesting question focused in my lab is how APCCdh1 
specifically recognizes such a diversity of substrates. My study showed that efficient 
degradation of all APCCdh1 substrates that I tested requires functional D-box receptor on 
Cdh1, including those without conventional D-box motif. This observation suggests the 
universal existence of D-box on APCCdh1 substrates. In contrast, the KEN-box receptor is 
only required for proteolysis of a subset of Cdh1 substrates including those lacking 
consensus KEN sequences, and the ABBA motif receptor only for Cik1.  
        My study revealed the D-box and/or KEN-box receptors dependency of some 
APCCdh1 substrates which were not identified before. KEN-box receptor was required by 
Ase1 for degradation, although previous study only reported a D-box in Ase1, since KEN-
box had not been identified when Ase1 was identified as an APC substrate. Actually 
several consensus KEN-box sequences exist in Ase1, and further studies mutating these 
motifs could be performed in future to identify the KEN-box on Ase1. Spo12 is another 
APCCdh1 substrate which was shown to require KEN-box receptor, as well as D-box 
receptor, for degradation in my study. However, previous study showed that the 
mutation of either consensus D-box or KEN-box sequences cannot stabilize Spo12, 
which may be due to the APC-independent degradation induced by the mutation of 
these degrons. Therefore, other methods need to be used to characterize the degrons 
on Spo12. For example, in vitro ubiquitination assay could be used with purified APC, 









        My study suggests that the current definitions of the three well-identified degrons 
(D-box, KEN-box, and ABBA motif) are still incomplete and need further characterization 
(on both sequences and higher structures). For example, current consensus D-box 
sequence was not identified on Cin8, Kip1, Cik1, Iqg1, Ase1, Sgo1, and Spo13 which all 
require functional D-box receptor for degradation. Current consensus KEN-box 
sequence was not identified on Kip1, Sgo1, and Spo13 which all require functional KEN-
box receptor for degradation. Current consensus ABBA motif sequence 
Fx(I/V/L)(F/Y/H)x(D/E) was not identified on Cik1 which requires functional ABBA motif 
receptor for degradation. Therefore, it is necessary to identify the functional degrons on 
these substrates, which will help better define the sequences, or higher structures that 
likely play more important role in substrate recognition, of these degrons.  
        Cik1 may serve as a good tool for this goal, since the 34 N-terminal amino acids 
were suggested to be critical for its APC-dependent degradation, although no canonical 
degron sequences such as D-box, KEN-box, and ABBA motif were contained in this 
domain. According to my study, D-box sequence is not limited to RXXL, and functional D-
box receptor is required for Cik1 degradation. These results together indicate the 
existence of D-box in the N-terminus of Cik1. Therefore, careful examination on this 
region is required in future study to identify the D-box with unconventional sequence. 
For example, according to the sequence alignment of the D-boxes from different APCCdh1 
substrates and Acm1, L is the most critical residue in D-box consensus sequence 
compared with R. Moreover, the alignment of the DBEs suggests that acidic residues (D 
and E) are not found on the first two positions of the DBE in substrates, although little 
sequence conservation was exhibited by these APCCdh1 substrates (Figure 4.5.1.). These 
information may not be exactly accurate, but could help identify the D-box in the N-
terminus of Cik1. Alanine scanning could be used. The potential D-boxes which meet 
these two criteria can be mutated to alanine, and the stabilities of these mutant 
proteins can be monitored in G1-arrested cells to identify the true D-box. Moreover, the 
identified D-box as well as its extension can be fused with protein A, and the stability of 








functional D-box. In future, structural study will be helpful to identify the higher 
structures shared by the degrons without consensus sequences but able to bind the 
same degron receptors on APCCdh1.       
 
5.2 Additional functions of D-box besides guiding substrate binding as a degron 
 
        D-box was the first APC degron identified to bind the WD40 domain of both Cdc20 
and Cdh1, as well as the Apc10 subunit. Compared with the selective requirement of 
KEN-box and ABBA motif, my study revealed a broad requirement of the D-box receptor 
on Cdh1 for the degradation of various APCCdh1 substrates, even including those without 
conventional D-box consensus sequence. Such broad requirement of the D-box receptor 
on Cdh1 for substrate degradation indicates that D-box may be involved in other 
substrate ubiquitination events other than APCCdh1 binding. Moreover, my study 
characterized the DBE which plays an important role in substrate degradation and 
contributes to a complete D-box. This discovery not only explains why is RXXL sequence 
found on thousands of proteins most of which are clearly not APC substrates, but also 
suggests the more important roles D-box plays in regulating substrate ubiquitination, 
such as controlling the positioning or binding of the E2 which was suggested by previous 
study [148], or orienting substrate lysines through the appropriate secondary structure. 
        Recent structural studies indicate that D-box is a bipartite degron which consists of 
a coactivator-interacting N-terminal (RxxL) motif, and an APC10-binding C-terminal 
motif [24]. Since Cdh1 was shown to function in substrate lysines positioning for 
ubiquitin transfer and the conformational change of APC to facilitate the positioning of 
RING module, which is important for substrate ubiquitination by APC [24], D-box as well 
as its extension binding to both Cdh1 and APC10 may also function in these key events. 
Therefore, more study on the mechanism of broad D-box requirement is required in 
future, which will uncover the diverse roles D-box plays in regulating APC substrate 
ubiquitination. Structural study revealing the details of the interaction between D-box 








5.3 ABBA motif identification on more APCCdh1 substrates 
 
        ABBA motif was originally identified in the central inhibitory domain on Acm1, and 
it is required for APCCdh1 inhibition [108]. Then it was shown to be shared by human 
Cyclin A, BubR1, and Bub1, as well as budding yeast Clb5, and contribute to APCCdc20 
binding [97-99]. No previous study ever showed it is a degron for APCCdh1. My study 
revealed for the first time that the ABBA motif can also function as a degron for APCCdh1 
in Cik1 (and Acm1∆52 when the D-box is mutated). After testing a subset of APCCdh1 
substrates which do not require KEN-box receptor on Cdh1 for degradation, Cik1 was 
found to be the only APCCdh1 substrate that requires ABBA motif receptor for 
degradation. However, this cannot exclude the possibility that ABBA motif also exists on 
other APCCdh1 substrates, as I have only tested a subset of them. Moreover, another 
possible reason for the negative results of ABBA motif receptor assay is the APCCdh1 
substrates which showed no dependence on ABBA motif receptor are highly dependent 
on D-box and KEN-box for degradation. The interactions between D-, KEN-boxes and D-, 
KEN-box receptors are sufficient to promote the degradation of these APCCdh1 substrates. 
These APCCdh1 substrates may have ABBA motif whose interaction with APCCdh1 also 
contributes to substrate degradation, although to a lesser extent compared with D- and 
KEN-boxes. This hypothesis is supported by the observation that some substrates do 
have some residual degradation in the strain with D-box receptor mutant Cdh1, 
compared to when Acm1 is overexpressed (Chapter 3). Therefore, the ABBA motif 
dependence needs to be tested in a strain that already has a mutation in the KEN-box 
receptor, or even the D-box receptor. The identification of ABBA motif on more APCCdh1 












5.4 Additional binding sites on Cdh1 besides D-box, KEN-box, and ABBA motif 
 
        My study suggest that some APCCdh1 substrates require more than one substrate 
binding site on Cdh1, while others only require one—the D-box receptor. This 
observation implies the existence of additional docking sites on Cdh1 which remain 
unknown, since it is hard to explain why some substrates only use one but others use 
multiple degrons, and how a single D-box alone can provide sufficient affinity and 
specificity for APCCdh1 binding. Compared with D-box which is universally required and 
may be involved in more events than substrate binding, KEN-box and ABBA motif may 
mainly contribute to the affinity and specificity of APCCdh1 binding. The use of various 
additional degrons, such as KEN-box, ABBA motif, and other unidentified short motifs 
for APCCdh1 binding, allows high selectivity in substrate binding which is critical for 
flexibility in the substrate structural requirements. Therefore, future study should be 
focused on the substrates which do not require KEN-box and ABBA motif receptors for 
degradation, such as Nrm1, Mps1, Fin1, and Cdc20, to identify more motifs responsible 
for APCCdh1 binding. The APCCdh1 substrates which have residual degradation in the strain 
with D-box receptor mutant Cdh1, compared to when Acm1 is overexpressed, but not 
dependent on KEN-box receptor for degradation should also be focused to detect 
potential degrons. Sequence alignments of these APCCdh1 substrates in different fungal 
species would be helpful to identify conserved motifs besides conventional D-box. Then, 
these motifs could be mutated to alanine, and the stabilities of these mutant proteins 
could be monitored in G1-arrested cells. If the mutations of the motifs can stabilize 
APCCdh1 substrates, the motifs as well as NLS could be fused with protein A to test 
whether they are sufficient to promote protein A degradation. The identification of new 
degrons would further help identification of the degron receptors on Cdh1 in future. If 
possible, structural studies on APCCdh1 and these substrates will be helpful to 









5.5 Mechanism of APC inhibition by Acm1 
 
        Acm1 as a pseudosubstrate inhibitor has been implicated in regulation of APCCdh1, 
which is critical for cell cycle regulation. However, it was not understood what makes 
Acm1 an inhibitor rather than a true APC substrate, specifically, how Acm1 evades 
ubiquitination and degradation by APCCdh1. Several models explaining the inhibitory 
function of Acm1 were proposed previously. One model suggested that Acm1 evades 
APCCdh1-mediated degradation by utilizing the additional APCCdh1 binding sites, ABBA 
motif and K-motif, which confer Acm1 extremely tight binding on APCCdh1, as well as the 
inaccessibility of ubiquitinatable lysines [108]. Another model attributes the inhibitory 
function of Acm1 to its unique D- and KEN-box sequences, which was supported by the 
observation that Acm1 can be converted into an efficient APCCdh1 substrate in vitro by 
mutating its D-box and KEN-box [115]. 
        In my study, a D-box with a unique extension was identified responsible for the 
inhibitory function of Acm1. Indeed, the first three residues in this region together 
distinguish a pseudosubstrate of APCCdh1 from true substrates. Mutating this region to 
either the corresponding one in Hsl1 or just alanine residues was sufficient to convert 
Acm1 into an efficient APCCdh1 substrate, and true APCCdh1 substrates can be stabilized 
by replacing this region with either the corresponding one in Acm1 or just alanine 
residues. The most surprising observation is that the mutant APCCdh1 substrates with the 
DBE replaced with the corresponding one in Acm1 acquired inhibitory function, 
although not as strong as Acm1, which could be attributed to the weaker binding affinity 
due to the lack of additional binding sites.  
        Compared with previous models, my model looks more convincing, since this is the 
first time that true APCCdh1 substrates can be converted into pseudosubstrates by 
mutating just 3 residues. My study also rules out the other models previously proposed. 
ABBA motif contributes to APCCdh1 binding of Acm1, however, it is not responsible for 
preventing Acm1 from APCCdh1-mediated degradation, since its mutation cannot 








consensus sequence of the D-box in Acm1 is not different from the D-boxes in true 
APCCdh1 substrate, since it is the DBE that plays a decisive role in distinguishing a 
pseudosubstrate inhibitor of APCCdh1 from true substrates.  
        In future, more mutation could be made on true APCCdh1 substrates to increase their 
inhibitory function, for example, adding additional binding sites such as KEN-box and 
ABBA motif. Short synthetic peptides with D-box, proper DBE as well as additional 
binding sites will be tested for APCCdh1 inhibition. Moreover, the structures and 
sequences of other APC inhibitors in various species, especially those with unknown 
mechanisms of APC inhibition, could be examined to determine whether similar 
inhibitory D-boxes are utilized. The identification of the DBE similar to that in Acm1 
would imply a similar mechanism utilized by Acm1. 
        Another interesting question is how Acm1 evolved to become a potent 
pseudosubstrate inhibitor of APCCdh1. One possible mechanism is that Acm1 evolved 
from a true APCCdh1 substrate, since significant structural similarities are shared by Acm1 
and true APCCdh1 substrates. There is nothing different between Acm1 and true APCCdh1 
substrates except a unique DBE in Acm1. However, it is not understood what 
significance it has, if this hypothesis is true. A possible advantage of this mechanism is 
that this is a relatively easy way for the organisms to acquire inhibitors of APC compared 
with other methods. Therefore, this may suggest the existence of the similar 
mechanisms utilized by other APC pseudosubstrate inhibitors in other organisms. 
 
5.6 Molecular function and conservation of DBE 
 
        As my study show the decisive role the DBE plays in distinguishing pseudosubstrates 
from true substrates, it is important to understand how this region functions in 
substrate ubiquitination by APCCdh1. My study suggest that the DBE does not contribute 
to APCCdh1 binding of the substrates, but their ubiquitination. This observation supports 
my hypothesis that D-box plays more important roles in substrate ubiquitination, 








specificity of APCCdh1 binding. This could also help explain why D-box receptor is broadly 
required for substrate degradation. However, how DBE functions in promoting substrate 
ubiquitination is still largely unknown, particularly, how DBE interacts with Cdh1 and 
core APC is not understood. Therefore, future work should be focused on detecting the 
interaction between DBE and APCCdh1 by using both structural and biochemical methods. 
For example, in vitro ubiquitination assay with purified E1, E2, core APC as well as Cdh1 
would be performed with different peptides containing the DBEs from various APCCdh1 
substrates and Acm1. This assay would help determine whether DBE is responsible for 
the ubiquitination of APCCdh1 substrates. Comparison of the high-resolution structure of 
apo APC and APCCdh1 with the DBE in substrates would be helpful to identify the 
conformation changes needed for activity. 
        Another question that remains to be answered is how conserved the DBE is. 
Different from the core D-box whose consensus sequence RXXL has been identified on 
many substrates, DBE from different APCCdh1 substrates show little similarity in their 
sequences, even in the first three residues which were shown extremely critical in this 
region. However, my study suggests the existence of functional conservation on DBE in 
both APCCdh1 true substrates and pseudosubstrate inhibitor, since mutating the D-box 
extension to alanine residues can completely stabilize Fin1, as well as converting Acm1 
into a true APCCdh1 substrate. Therefore, the most likely explanation is that the 
conservation exists in higher structure but not the linear sequence of this region, which 
means the higher structure of DBE region needs to be carefully examined in future. 
Cryo-electron microscopy is the most efficient tool to reveal the similarity of higher 
structure of DBEs in different APCCdh1 substrates while bound to the core APC if possible. 
Without the structures of DBEs in APCCdh1 substrates, sophisticated bioinformatic tools 
which can predicate similarities at structural levels beyond primary sequence will also 










5.7 Different substrate specificities of APCCdc20 and APCCdh1 
 
        Cdc20 and Cdh1 as two APC co-activators associate with APC in different cell-cycle 
phases. APCCdc20 and APCCdh1 recognize different subset of substrates with some 
overlapping, and the mechanism of their different substrate specificities is largely 
unknown. Since Cdc20 functions as an oncogene whereas Cdh1 plays a critical role in 
mitotic exit and G1 maintenance as a tumor-suppressor, it is ideal to inhibit just APCCdc20 
but not APCCdh1. Theoretically this can be achieved since APCCdc20 and APCCdh1 recognize 
different subset of substrates (with some overlapping), and nature has evolved specific 
inhibitors for them, such as MCC, Emi1, Acm1, and et al. Therefore, understanding the 
mechanism of the different substrate specificities of APCCdc20 and APCCdh1 is critical in 
developing better APC inhibitors.  
        Both Cdc20 and Cdh1 recognize their substrates via the degron receptors located 
on WD40 domains which share significant structural similarities, especially on D-box and 
KEN-box receptors. However, previous data and my study suggest that APCCdc20 and 
APCCdh1 recognize different D-boxes on Acm1 [109], and my study indicate this may be 
due to the different downstream regions of these two D-boxes. However, some 
substrates with only one well-identified D-box can be recognized by both APCCdc20 and 
APCCdh1, such as Clb2 and Pds1, which suggests that APCCdc20 and APCCdh1 may recognize 
the D-box with same extension region. Therefore, to test whether any different 
properties exist between the N-terminal D-box recognized by APCCdc20 and the central D-
box recognized by APCCdh1 in Acm1, the extension regions of these two D-boxes could be 
switched to test whether the co-activators recognizing them are also switched. The 
positive result would suggest the critical role DBE plays in determining which D-box to 
be recognized by APC with certain co-activator. Another possible mechanism is that 
APCCdc20 and APCCdh1 recognize different ABBA motif, as the ABBA motif on Clb5, an 
APCCdc20 substrate, is distinct from the ABBA motif on Acm1 that binds APCCdh1. This is 
also supported by the differences on the ABBA motif receptors of Cdc20 and Cdh1, 








may also contribute to the different substrate specificities of APCCdc20 and APCCdh1 such 
as KEN-box and other unidentified degrons which are largely unknown. Compared with 
D-box and KEN-box receptors whose sequences and structures are highly conserved, 
other unconserved domains on Cdc20 and Cdh1 may be responsible for their different 
substrate specificities. Therefore, the identification of novel binding motifs and degron 
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